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Abstract 
Development of a protective vaccine against the human immunodeficiency virus 
(HIV-1) has failed so far. In almost all vaccination strategies, the neutralizing antibody 
titers elicited against the pathogen defines protective immunity. Unfortunately, most 
antibody responses against HIV-1 in an acute infection are only strain-specific and 
quickly bypassed by escape mutations. Therefore, eliciting a broad, strain-independent 
immune response that affects essential portions of HIV-1 are considered crucial 
requirements for a valuable vaccine. An ever increasing number of broadly neutralizing 
antibodies (bNAb) against the HIV-1 envelope (Env) have been discovered so far. 
Vaccination trials designed to re-elicit bNAbs that mediate protective immunity have 
remained futile (reverse vaccinology). Recent discoveries suggest that a membrane-
bound, trimeric state of Env used as immunogen is essential for stimulating 
neutralizing antibody responses. 
Therefore, a discovery platform was developed in order to select trimeric envelope 
variants that are displayed on the surface of mammalian cells. bNAb staining of Env 
displaying cells was suggested to allow screening for Env variants with the highest 
affinity. Using iterative rounds of selection strong binding Env variants should be 
enriched, allowing isolation of the highest affinity Env candidate (Panning). Several 
display and selection techniques were evaluated, including lentiviral and cellular 
display, as well as microtiterplate, MACS, and FACS-based selection methods. Finally, 
an HIV-1 derived lentiviral vector was developed to infect HEK293T cells at a low 
multiplicity of infection (MOI), in order to link phenotype and genotype. The vector was 
designed and proven to express both GFP and Env in a constant relationship that 
enables indirect normalization of produced Env by detecting GFP. Hence, infected 
cells expressing GFP concurrently display membrane-anchored Env proteins on their 
surface. Subsequently to staining with an appropriate bNAb, Env-displaying cells were 
selected for high affinity binding via FACS sorting. A small “model” library of Env 
variants with distinct binding capacities against the bNAb 447-52D was used for 
evaluation. In a proof-of-concept study, it was demonstrated that the Env variant with 
the highest affinity to the applied bNAb was enriched in two rounds of selection (up to 
∼10-fold). Hence, the technique provides the possibility to screen for membrane-bound 
Env variants with high binding capacities against the bNAb applied. 
Nevertheless, the lenti-cellular display and FACS-mediated panning platform 
developed in this thesis needs further optimization, it needs to be challenged by 
libraries of larger diversity, and selected candidates should be evaluated in vaccination 
trials.  
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Zusammenfassung 
Die Entwicklung eines wirksamen Impfstoffs gegen das humane Immundefizienz-Virus 
(HIV-1) gilt bis heute als ein ungelöstes Problem. Bei fast allen gängigen Impfstoffen 
beruht die Wirksamkeit auf der Bildung von Pathogen-neutralisierenden Antikörpern. 
Die Antikörper, die bei einer akuten HIV-1-Infektion überwiegend entstehen, erreichen 
jedoch nicht die gewünschte Neutralisation, weil die Ziel-Epitope aufgrund der bei HIV 
in hohem Maße auftretenden Mutationen schnell verändert werden. 
Als zwingende Eigenschaft für ein erfolgreiches Vakzin gilt daher, dass es eine 
Immunantwort gegen essentielle Bestandteile des HI-Virus auslöst und somit ein 
möglichst breites Wirkspektrum aufweist. Einige sogenannte „breit neutralisierende 
Antikörper“ (bNAbs) sind bereits länger bekannt und wurden ausgiebig charakterisiert. 
In jüngster Zeit wurden in steigendem Maße weitere vielversprechende bNAbs isoliert 
und Ihre Eigenschaften sind derzeitiger Bestandteil vieler Forschungsbemühungen. 
Diese Antikörper sind in der Lage, das Oberflächenprotein (Env) von nahezu allen 
bekannten HI-Viren zu binden und den Infektionsmechanismus zu unterbrechen. Eine 
Vielzahl von Versuchen, Antikörper mit ähnlichen Eigenschaften durch Impfungen zu 
induzieren, blieb jedoch bisher erfolglos („reverse vaccinology“). Neueren 
Erkenntnissen zufolge sind vermutlich membrangebundene, trimere Env-Proteine als 
Vakzin nötig, um die gewünschte Immunantwort zu vermitteln.  
In der vorliegenden Arbeit wurde eine Selektionsmethode entwickelt, bei der Varianten 
trimerer Env-Proteine auf der Oberfläche von Säugetierzellen präsentiert werden. Die 
unterschiedlichen Bindungsstärken der verwendeten Env-Varianten zu einem 
gegebenen bNAb sollten es hierbei ermöglichen, auf Env-Varianten mit der höchsten 
Affinität zu selektionieren. Durch Wiederholungen des Prozesses sollten Env-
Varianten mit höherer Affinität angereichert und schließlich die Variante mit höchster 
Affinität isoliert werden (Panning). 
Es wurden verschiedene Methoden sowohl zur nativen Env-Präsentation als auch  
Selektion evaluiert. Hierbei wurde Env entweder direkt auf HI-Viren oder HEK293T 
Zellen präsentiert und mittels Mikrotiterplatten-, MACS- oder FACS-basierten 
Methoden selektioniert. Dies mündete in einem sogenannten „lenti-cellular display“ 
und FACS-basierten Panning. Um hierbei die Verknüpfung von Phäno- und Genotyp 
zu gewährleisten wurde ein lentiviraler Vektor genutzt, und HEK293T Zellen wurden 
mit einer geringen Infektionsrate (low MOI) infiziert. Dieser Vektor wurde dahingehend 
konstruiert, dass ein ebenfalls auf dem Vektor codiertes GFP in konstantem Verhältnis 
zu dem präsentierten Env exprimiert wird. Dadurch wurde es möglich, das GFP-Signal 
zu nutzen, um indirekt auf die Mengen des produzierten Env zu normalisieren und 
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spezifisch mit einem bNAb nach hoch affinen Env-Varianten mittels FACS zu 
selektionieren.   
Der entwickelte Anreicherungsprozeß wurde mit einer Modell-Bibliothek evaluiert, die 
aus Env-Varianten mit bekannten Affinitäten zu bNAb 447-52D besteht. In dieser 
Studie konnte die Anreicherung der Env-Variante mit der höchsten Affinität zum 
verwendeten 447-52D Antikörper gezeigt werden (bis zu ~10-fache Anreicherung). Die 
entwickelte Panning-Methode eignet sich demnach zur Anreicherung und Isolierung 
von denjenigen Varianten einer Bibliothek von zelloberflächengebundenen Proteinen, 
welche die höchste Affinität zu dem eingesetzten Antikörper aufweisen. 
Nach weiterer Optimierung des vorgestellten Anreicherungsprozesses sollen zukünftig 
Bibliotheken mit höherer Variabilität eingesetzt werden, um Env-Varianten zu 
selektionieren, die in präklinischen und klinischen Studien auf ihr Potential zur bNAb-
Induktion untersucht werden sollen. 
Introduction 
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1. Introduction 
1.1 The HIV-1 epidemic  
Nearly 30 years have passed since the first reports and final identification of the 
human immunodeficiency virus-1 (HIV-1), as the cause for “Acquired Immune 
Deficiency Syndrome“ (AIDS) were published [1]. The “Joint United Nations 
Programme on HIV AIDS” (UNAIDS) [2] estimates that 33.3 million people were living 
with an HIV-1 infection at the end of 2009. That same year an estimated 2.6 million 
people became newly diagnosed with HIV-1 and 1.8 million AIDS-related deaths 
occurred. Sub-Saharan Africa continues bearing the biggest share of people living with 
HIV-1 infection (68% of the global total). Despite these high numbers the rate of AIDS-
related deaths decreased from a peak value of 2.1 million in 2004 to 1.8 million in 
2009. This decline reflects the increased availability of antiretroviral therapy (ART) [3]. 
Especially in Sub-Saharan Africa an estimated 20% less people died of AIDS-related 
causes in 2009 compared to 2004 due to a dramatically expansion of ART. 
To further control and finally end the HIV pandemic three essential steps are 
considered; (I) accelerating the implementation of available treatment and prevention 
tools such as ART and prevention methods tailored to local risk factors; (II) pursuing 
innovative research with the goal of eradication or control of HIV-1 in infected people 
without the need for lifelong ART treatment; (III) development of potent prevention 
tools that most likely are applied in various combinations depending on the target 
population [4,5].  
The outstanding impact of ART on the decrease of AIDS-related deaths is illustrated 
by the calculations provided by UNAIDS, and the estimation that an HIV-1 diagnosis 
with subsequent ART treatment, to date likely results in a life expectancy close to that 
of a healthy person [6]. Despite the advances in therapy, care and support, a lifelong 
treatment with daily dosing is associated with undesirable side effects, threat of 
chemoresistance and high economic costs, which limits part of the benefit to high-
income countries. Therapy and prevention tools like ART but also condoms and 
progress in microbicides [7] are very important, but requires both, a professional health 
care system asides a high level of compliance [8]. 
With the exception of one case-report [9], a true cure of an HIV-1 infected person still 
remains elusive. Different therapeutic strategies are being developed, but remaining 
challenges are especially latently infected resting cells, from which a rebound of virus 
replication can occur [10]. Therefore, the prevention of HIV infection with the use of a 
Introduction 
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safe, efficacious vaccine affords the best long-term solution to ending the HIV-1 
pandemic [11]. 
 
 
1.2 HIV-1  
The human immunodeficiency virus 1 (HIV-1) is an enveloped retrovirus of spherical 
morphology and 100-120 nm in diameter. The virus is enclosed by a lipid bilayer 
membrane that surrounds a cone-shaped capsid (core) encasing the viral genome 
consisting of two identical 9.2 kb RNA (+) strands (Fig. 1.1).  
 
      
Fig. 1.1 Schematic represantation of a mature HIV-1 particle 
 The lipid bilayer membrane is of host origin and includes approximately 10 trimeric 
envelope proteins (Env) [12]. The inner layer of the membrane is lined with matrix 
protein (MA), illustrated with a suggested gap at the position of budding. Capsid (CA) 
protein forms a cone-shaped core that bears two copies of nucleocapsid (NC)-
stabilized RNA genomes. The viral protease (PR), reverse transcriptase (RT), 
Integrase (IN) as well as Vpr and several other viral and host cell components with 
known or unknown functions are also located inside the virion core. Adapted from 
[13,14].  
 
Immature virus particles assemble at the membrane of an infected cell and 
subsequently are released surrounded with the lipid bilayer membrane of the cell in a 
process called budding [15]. Each particle is equipped with approximately 10 trimeric 
envelope (Env) proteins (see 1.3) [12,16,17] together with various host membrane 
proteins [18]. With a scheduled cleavage at 5 distinct sites of the Gag polyprotein by 
the viral Protease (PR), multiple domains (MA, CA, NC, p6, SP1, SP2) are separated 
and a rearrangement of the viral interior is induced. The complete process is called 
maturation and leads to a mature, infectious virus particle [14] (Fig. 1.1). 
The infection of a target cell is initiated by the attachment of the viral envelope 
glycoprotein (Env) to the cellular receptors CD4 and to one of the co-receptors (CCR5 
Trimeric envelope-glycoprotein (Env) 
Matrix (MA) 
Lipid bilayer membrane 
Capsid (CA) 
Nucleocapsid (NC) 
Enzymes/ Proteins 
(PR, RT, IN, Vpr, and others) 
Core: 
RNA genome 
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or CXCR4) of T-cells and macrophages. After endocytotic uptake and fusion of the 
viral and endosomal membranes [19], the viral core is released into the cytoplasm of 
the cell. Following an uncoating of the core, the viral genomic RNA is enzymatically 
reverse transcribed into double-stranded DNA by the viral RT. A preintegration 
complex is formed, by recruiting host cell proteins to the viral DNA genome, and is 
shuttled into the nucleus. The infection process is finalized with the integration of viral 
DNA into the host genome mediated by the viral enzyme Integrase (IN). Intrinsic host 
cell antiviral factors, such as TRIM5α [20], APOBEC3 [21] and Tetherin [22], are 
bypassed by HIV-1 acquired escape mutations [23], accessory proteins Vif (viral 
infectivity factor) [24] and Vpu (viral protein u) [22]. 
The replication of integrated provirus starts with a collaborative process of cellular and 
viral proteins. The cellular RNA-polymerase II mediates the transcription of full-length 
viral pre-mRNA that is spliced into several intron-free mRNAs coding for Tat, Rev and 
Nef. An enhanced transcription of viral mRNA is mediated by binding of the 
transcription factor Tat towards the viral LTR promoter [25]. Nef is an important factor 
for the pathogenicity of HIV-1 and the progression to AIDS, influencing multiple host 
cell processes [26]. The binding of Rev towards an mRNA intron element, the so-
called “Rev responsive element” (RRE), facilitates the export of singly and un-spliced 
mRNAs through the nuclear membrane [27] via the CRM-1 [28] export pathway. Thus, 
the synthesis of the structural proteins and enzymes Gag (MA-CA-SP1-NC-SP2-p6) 
[14], Gag-Pol (MA-CA-SP1-NC-SP2-p6*-PR-RT-IN) [29,30] and the envelope 
glycoprotein (Env) is enabled. Correspondingly, the localization of full-length viral 
genome RNA into the cytoplasm is ensured.  
The Env proteins are synthesized in the endoplasmic reticulum (ER) and migrate via 
the Golgi-Complex to the cellular plasma membrane, while Gag and Gag-Pol also 
locate to the plasma membrane, where they induce the assembly of virus particles. 
The formed particles comprise the viral enzymes, full-length viral RNA genome, 
cellular lys3tRNA (as primer) and several cellular compounds. By budding from the 
cellular membrane, the virions are surrounded with the Env containing lipid bilayer of 
the host cell. Thus, Env is like in all retroviruses the only viral protein that is accessible 
at the virion surface [31].   
Introduction 
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1.3 HIV-1 envelope glycoprotein (Env)  
The HIV-1 Env is translated as a precursor protein (gp160), which is heavily 
glycosylated in the ER and the Golgi providing a glycan-shield against neutralization 
[32]. Further on, it is cleaved into two subunits (gp120, gp41) by host furin proteases at 
the Golgi apparatus [31,33]. Trimeric complexes of non-covalently associated 
heterodimers consisting of a surface (gp120) and transmembrane (gp41)-subunit are 
incorporated into the host cell membrane. Therefore, Env is the only viral protein that 
is exposed on both the host cellular and viral membrane (Fig. 1.2). 
 
 
 
 
Fig. 1.2 HIV-1 envelope glycoprotein (Env) 
 A The full-length Env precursor gp160 is shown. Segments of gp120 and gp41 are 
designated as: C1–C5, conserved regions 1–5 / V1–V5, variable regions 1–5 / F, 
fusion peptide / HR1, heptad repeat 1 / C-C loop, the immunodominant loop with a 
conserved disulfide bond / HR2, heptad repeat 2 / MPER, membrane proximal 
external region / TM, transmembrane anchor / CT, cytoplasmic tail. Glycans are 
represented by tree-like symbols. Adapted from [34]. B-D Schematic representation 
of an HIV-1 Env protein incorporated into a lipid bilayer membrane, adapted from 
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gp41 also induces non-neutralizing antibodies, which are much more 
abundant in infected individuals than neutralizing ones. The non-
 neutralizing antibodies have been classified into two groups according 
to the location of their epitopes. Cluster I antibodies react with the 
immunodominant C-C loop of gp41 (residues 590–600), and cluster 
II antibodies recognize another immunodominant segment (residues 
644–663) next to the MPER27. Members in the latter group can bind 
HIV-1 gp41 with high affinity but have weak or no neutralizing or antivi-
ral activities28,29. The prototype of this group includes mAbs 98-6, 126-6, 
167-D, 1281 and 1379, isolated by immortalizing plasma B cells from 
HIV-1–positive people27,30–32. These mAbs seem to react optimally with 
gp41 in its postfusion conformation33, but they also bind ‘monomeric 
gp41’ (probably aggregated protein, as monomeric gp41 is not stable) 
and oligomer-specific conformations of gp41 (refs. 31,34). As the con-
formation of these envelope preparations has not been fully assessed, it 
remains uncertain which conformation(s) of gp41 the cluster II mAbs 
 recognize and why they are incapable of blocking HIV-1 infection.
Here we set out to investigate the structural basis for the drastic 
differences between the MPER-directed antibodies and the cluster 
II antibodies in their ability to neutralize HIV-1 infection. We have 
produced an improved gp41 construct to mimic its prehairpin-
 intermediate conformation. This protein binds tightly to broadly 
neutralizing antibodies 2F5, 4E10 and Z13e1 (ref. 35). We present 
biochemical and structural data to demonstrate that cluster II anti-
bodies to HIV-1 gp41 show high binding affinity for the postfusion 
conformation of gp41 and do not bind or bind only weakly to the 
stable, homogeneous gp41 preparations representing the prehairpin 
intermediate or the prefusion conformation. We propose that these 
antibodies are non-neutralizing because they target a late step in the 
viral entry process, when membrane fusion is likely to be complete. 
RESULTS
Production of GCN4-gp41-inter
In our previous studies, we have produced homogeneous preparations 
of trimeric HIV-1 envelope protein, derived from a clade A isolate, 
92UG037.8, to mimic its prefusion (gp140), prehairpin intermedi-
ate (gp41-inter) and postfusion (gp41-post) conformations (Fig. 1)9. 
We have demonstrated that the different conformational states of 
gp41 have markedly different antigenic characteristics. In particular, 
two MPER-directed neutralizing antibodies, 2F5 and 4E10, inhibit 
HIV-1 infection by targeting the prehairpin-intermediate state of gp41 
(refs. 9,26). To define the conformational state recognized by anti-
gp41 cluster II antibodies, we sought to test their reactivity to gp140, 
gp41-inter and gp41-post. gp41-inter was designed to capture gp41 in 
the extended, prehairpin-intermediate confor ation with the follow-
ing sequence: (HR2)–linker–(HR1–C-C loop–HR2–MPER)–(trimer-
ization foldon tag) (Fig. 1). This construct can be pictur d as the 
prehairpin intermediate captured by a c valently linked HR2 peptide, 
such as T20. When gp41-inter chains trimerize, the N-terminal HR2 
segments (T20) form a six-helix bundle with the HR1 segments, 
whereas the C-terminal HR2 segments, constrained by the foldon 
tag, are unable to form a six-helix bundle. Thus, the two copies of HR2 
in gp41-inter are in distinct conformations: the N-terminal HR2 is in 
the six-helix, postfusion state, and the C-terminal HR2 mimics the 
prehairpin intermediate. Using gp41-inter as a reagent to analyze anti-
bodies directed against HR2, such as cluster II mAbs, would compli-
cate data interpretation. We therefore designed a modified gp41-inter 
in which the entire six-helix bundle (the segment HR2-linker-HR1) 
was replaced with a trimeric GCN4-derived coiled coil to generate 
GCN4-gp41-inter (Fig. 1)36. The heptad repeat of GCN4 needed to be 
in the same register as the HR1 region of gp41 to avoid any structural 
distortion. GCN4-gp41-inter was expressed in Escherichia coli and 
refolded in vitro with the same protocol we developed for gp41-inter 
(see ref. 9 and Online Methods). As expected, purified GCN4-gp41-
inter is also a monodisperse trimer and is stable after several rounds 
of gel-filtration chromatography (Supplementary Fig. 1).
To confirm that replacement of the six-helix bundle with GCN4 
does not alter antigenic properties of gp41-inter, we carried out 
binding experiments using surface plasmon resonance (SPR) to 
assess reactivity of GCN4-gp41-inter to three MPER-directed mAbs, 
2F5, 4E10 and Z13e1. Both gp41-inter and GCN4-gp41-inter pro-
teins showed the same kinetic profile for binding to the antibodies 
(Supplementary Fig. 2 and Supplementary Table 1), indicating that 
the conformation of MPER is identical in the two constructs. We 
note that Z13e1, the least potent neutralizing antibody among the 
three, dissociated from gp41 much more rapidly that did 2F5 and 
4E10, consistent with our earlier suggestion that a slow dissociation 
rate of antibody–gp41 complex may be crucial for the neutralizing 
activity of MPER-directed antibodies26. The interactions of gp41 
with the three antibodies fit well to the 1:1 Langmuir binding model 
(Supplementary Fig. 2). Moreover, both gp41-inter and GCN4-
gp41-inter formed tight complexes with cluster I antibodies, such 
as 240-D and 246-D27, which we were able to purify by gel-filtration 
chromatography (data not shown), suggesting that substitution of 
gp160 C1 V1 V2 V3 V4 C4C2 C3 V5 C5
F HR1 HR2 TM
MPERC-C loop
gp41-post
gp41-inter
gp140 C1 V1 V2 V3 V4 C4C2 C3 V5 C5
Fd His
Linker HR1 HR2 MPERC-C loop FdHR2
Linker
CT
GCN4-gp41-inter
GCN4
Figure 1 HIV-1 envelope constructs and GCN4-gp41-inter. Top, schematic 
representation of HIV-1 envelope glycoprotein gp160, the full-length 
precursor. Segments of gp120 and gp41 are designated as follows: 
C1–C5, conserved regions 1–5; V1–V5, variable regions 1–5; F, fusion 
peptide; HR1, heptad repeat 1; C-C loop, the immunodominant loop with 
a conserved disulfide bond; HR2, heptad repeat 2; TM, transmembrane 
anchor; CT, cytoplasmic tail. Glycans are represented by tree-like 
symbols. HIV-1 envelope constructs used in this study include gp140, 
the uncleaved ectodomain of gp160 with a trimerization foldon (Fd) tag 
and a histidine tag at its C terminus; gp41-post, gp41 in the six-helix 
conformation with partial MPER; gp41-inter, HR2 peptide– and foldon 
tag–trapped gp41 in the prehairpin-intermediate conformation; GCN4-
gp41-inter, gp41-inter with the six-helix-bundle portion replaced with a 
trimeric GCN4 coiled coil36 (in light blue). Bottom, diagrams representing 
three-dimensional organization of gp41-inter and GCN4-gp41-inter. The 
trimeric GCN4 with its heptad repeat in the same register as HR1 replaces 
the HR2-linker-HR1 of gp41-inter. The coordinates of HR1 (ref. 11) and 
GCN4 (ref. 36) coiled coils are shown in yellow and light blue, respectively.
A R T I C L E S
A 
gp120 gp41 
B C D 
(1) 
(2) 
E 
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White et al. [35]. Trimeric Env consist of the non-covalently bound subunits gp120 
(red) and gp41 (blue). The position of the CD4 receptor-binding site is indicated in 
yellow. The induced conformational change after the binding of Env towards the CD4 
receptor is proposed as a B “closed” and C “open” state. C The attachment process 
of HIV-1 to a CD4+ target cell is illustrated. (1) Binding to the CD4 receptor (yellow) 
induces the “open state” conformation of Env and (2) enables for the subsequent 
binding to the co-receptor (purple) (CCR5 or CXCR4). E Upon cellular receptor 
recognition, gp120 and gp41 undergo conformational changes resulting in exposure 
of the N-trimer and its hydrophobic pocket in the prehairpin intermediate. Formation 
of the trimer-of-hairpins structure juxtaposes cellular and viral membranes and 
causes fusion. The gp41 fusion peptide (orange) and transmembrane domain 
(purple) are also shown. Note that gp120 is omitted for clarity reasons from the 
prehairpin intermediate. Adapted from [36].  
 
Comparison of Env gene sequences from multiple HIV-1 isolates identified a high 
degree of variability in the gp120 subunit, referring to as five variable domains (V1–V5) 
interspersed with five relatively constant domains (C1–C5) (Fig.1.2. A). Typically, 
gp120 comprises 18 Cysteine (Cys) residues that are covalently bound to form 9 
disulfide bridges. V1 is separated from V2 by two disulfide bonds, while the two loops 
are contained in a larger loop by another disulfide bond. V3 and V4 loops are also 
delimited by a disulfide bond [33]. The V1/ V2 loop can range in length between 50 to 
90 aa, while the length variation of V4 and V5 loops ranges from 19 to 44 aa and from 
14 to 36 aa, respectively. The V3 loop and C2, C3, and C4 domains show relatively 
little length variation. Furthermore, a correlation exists between an increase in length 
and number of glycosylation sites in V1/V2 and disease progression, suggesting that 
modification of V1/ V2 length may promote escape from the host humoral immune 
response [37]. 
Approximately half of the molecular mass of gp120 is composed of N-linked glycans, 
[38] with a small additional contribution from O-linked sugars [39] (see Fig. 1.2 A). 
There are 20–35 N-linked glycosylation sites in gp120 and 3–5 N-linked glycosylation 
sites in gp41 that mask Env from host immune recognition [40], contribute to Env 
folding [41], and help virions bind to the host cell surface [42].  
The target cell tropism is determined by the sequentially binding of the subunit gp120 
to CD4 and a coreceptor CCR5 or CXCR4. The CD4 receptor-binding site is formed 
from the conserved residues in discontinuous regions that are folded into proximity in 
the Env tertiary structure. Particularly C1, C3, and C4, were found to be the principal 
Env determinants that bind CD4 [43]. Notably, it was recently shown that the contact 
sites of CD4 can also comprise all constant regions C1-C5, utilizing an Alanin-based 
library of gp120 mutants (primary isolate: JRCSF) as demonstrated by Li et al. [44]. 
Several studies have shown that the V3 loop is important for membrane fusion [45] 
and coreceptor specificity [46]. It also contains dominant epitopes recognized by 
neutralizing antibodies [47,48]. The switch from CCR5 to CXCR4 tropism driven by V3 
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mutation has been linked to an increase in the net positive charge of V3, allowing an 
interaction with the negatively charged surface of CXCR4 [49]. 
The fusion of the viral lipid envelope with the host cell membrane is mediated by the 
gp41 subunit, subsequently to the attachment of gp120 to the target cell receptors. 
Gp41 is composed of ∼345 aa, organized into three major domains: an extracellular-, 
transmembrane- (TM), and a C-terminal (CT) -domain (Fig. 1.2 A). The extracellular-
domain comprises the major fusion determinants, known as the fusion peptide (F) [50], 
an immunodominant C-C loop [34], two hydrophobic regions that form α-helical coiled-
coil structures referred to as the heptad-repeat regions HR1 and HR2 [51], and a Trp-
rich domain referred to as the membrane-proximal external region (MPER) [52]. A 
disulfide bridge within the hydrophilic C-C loop connects HR1 and HR2, and their 
interaction drives the fusion process. The fusion peptide is usually buried in the gp120/ 
gp41 quaternary complex.  
Recently, there has been great progress in the visualization of protein assemblies 
combining two methods, medium-resolution cryo-electron tomography (cryo-ET; 
macromolecular architecture) [53] and high-resolution X-ray crystallography (molecular 
structure) [53,54]. Utilizing this combination of methods by fitting the available crystal 
structures of Env into the corresponding density maps of cryo-ET extended the 
knowledge about the structural organization of native, trimeric and membrane-bound 
Env. Comparative analyses of both CD4-dependent and -independent strains, derived 
from HIV-1 and SIV (Simian immunodeficiency virus) showed different ”open” or 
“closed” quaternary conformations [35] (Fig. 1.2 A/B). It is proposed that the CD4 
dependent Env “spike-opening” process is an evolutionarily adapted mechanism to 
protect Env sites prone to be targeted by neutralizing antibodies, until the attachment 
to the target cell occurs. This model is supported by strains bearing CD4-independent 
Env that are more sensitive to neutralization than CD4-dependent strains. Taken 
together, these results are a further hint to the proposed model that the requirement of 
a sequentially two-step binding process to CD4 and subsequently to CCR5 or CXCR4 
(Fig. 1.2 C), is an evolutionary adaptation to protect the virus from the host immune 
system [35,55]. Upon binding to its receptors several conformational changes are 
induced that trigger refolding events in gp41. (I) The prehairpin intermediate is an 
extended conformation of gp41 and allows inserting its N-terminal hydrophobic fusion 
peptide (F) into the target cell membrane, thus initiating the fusion process. (II) The 
Trimer-of-hairpins (six-helix bundle) conformation is reconstituted, by forming a bundle 
of three HR1 motifs and fold over a hydrophobic pocket antiparallel to three HR2 
domains. Therefore, the fusion peptide and the transmembrane domain of gp41 are 
placed at the same end of the molecule. This irreversible refolding of gp41 effectively 
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brings the two membranes together, thus causing membrane fusion [36]. (III) The 
Post-fusion conformation is the most stable state and probably serves as a decoy for 
the host immune system, as it induces ineffective antibody responses in infected 
people [34] (Fig. 1.2 E) [36,56]. 
 
 
1.4 Vaccination 
In general a vaccine mediates the protection of an organism from an infection with the 
respective pathogen or at least from the disease caused by the pathogen. Therefore, 
vaccination is mainly used as a prophylactic method establishing immunity that 
protects enduringly against the respective pathogen. Generally, two strategies, the 
passive and active immunizations, are distinguished. (I) For passive immunizations, 
immunoglobulin is administered to deactivate the pathogen before it infects the 
organism. Thus, it has to be administered within a certain timeframe and with an 
effective dosage and sometimes in combination with active vaccines [57]. (II) For an 
active immunization, a vaccine is administered mediating a long-lasting protection by 
activating the organism’s immune system and leading to immunological memory.  
The concepts of an innate and adaptive immune response have been reviewed 
extensively, though not completely explored [58-63].  
Here, only the adaptive immune system with its main concepts is described to highlight 
how vaccination is related to protection. The T- and B-cell compartments of the 
immune system generally work in concert to provide such a protective immunity 
against pathogens.  
B-cells develop from hematopoietic stem cells located in the bone marrow of adults 
and are genetically committed to express antibodies distinct from that of 
accompanying B-cells. Early in development the contact with autologous peptides lead 
to apoptosis, thus a self tolerance is achieved [64]. Immature B-cells characteristically 
display membrane-bound IgM via the B-cell-receptor (BCR) and migrate from the bone 
marrow. They can be divided into two subsets of cells (B1/ B2), referring to their 
location and mode of activation. Further development through intermediate stages 
results into mature naïve B-cells that express both membrane-bound IgM and IgD [65]. 
Besides some cells that settle at the marginal-zone of the spleen, most cells continue 
circulating until they encounter their cognate antigen (follicular B-cells), or undergo 
apoptosis. Stimulation by a related antigen induces apoptosis or activates the B-cell, 
depending on the development stage and if additional signals are present. Once 
activated, the cells display membrane-bound fragments of the antigen and enable the 
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binding of specific T helper cells (CD4+). Upon attachment, those cells help inducing 
the transition of B-cells to form germinal-centers in which their antibody-genes are 
heavily rearranged. This includes so-called class-switch recombination and somatic 
hypermutations, leading to a self-antigen cleared and affinity enhanced IgG antibody 
secretion [58]. From this state cells can develop into: (I) long-lived memory B-cells, 
which have cell-surface-, not-secreting- antibody, and are quick responding to 
recurring antigen activation events, (II) short-lived plasma cells, which are stationary 
and antibody secreting. Upon a recurring activation, memory cells differentiate into 
rapidly dividing, migratory plasmablast (secondary immune response). These cells 
already secrete antibodies and are competent to form long-lived plasmacells, 
producing large volumes of antibodies. Notably, plasmablasts can also develop from 
any other type of activated B-cell, as well as class-switch and hypermutation events 
were reported to occur outside germinal-centers, but remained unclear in their efficacy 
[66]. The maintenance of serum antibody concentrations is a characteristic of the 
secondary immune response, due to the quick responding memory- and development 
of long-lived plasma-cells [59]. An immediate protection in the case of an infection is 
mediated by long-lived plasma cells that are present in the bone marrow and secrete 
antibodies in an antigen-stimulus independent fashion, thus maintaining sufficient 
amounts in serum and body fluids [60].  
Similar functionalities apply to CD8+ cytotoxic T lymphozytes (CTL). A specific T-cell 
receptor (TCR) mediates the contact to its cognate antigen. Infected cells display 
target antigens on their surface via MHC class I molecules. Upon detection by CTLs, 
targeted cells undergo apoptosis or get lysed. As an example, in the case of acute 
HIV-1 infections, though no sterile immunity is reported, a correlation between the 
appearance of specific CTLs and a decline of primary viremia were demonstrated 
[67,68].     
The detailed interplay between the cellular (T-cell) and humoral (B-cell) immunity is still 
not entirely understood. Yet, basically CTLs (CD8+) are considered necessary to 
control viral replication. Whereas T-helper-cells (CD4+) “help” stimulating B-cells, thus 
inducing antibody secretion that can prevent viral infections of host cells. 
To date, almost all licensed vaccines against viral pathogens, protect due to the 
induction of pathogen specific antibodies by B-cells. Whereas T-cells, besides their 
help to B-cells, are more important in the control of an established infection. This 
paradigm is not strict, as demonstrated for the varicella-zoster virus [69,70], but rather 
a relative and statistical truth and subject to variation from one infection to another. 
Shortly, the importance of either B-cell or T-cell immunity is still subject of considerable 
research and debate [62,63]. Despite the widespread practice of determining antibody 
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titers to predict the efficacy of vaccines, exploration of the immunological mechanisms 
of vaccinations, defining correlates of protective immunity and their efficacy are still 
ongoing, as reviewed in Pulendran et al. [61,71].  
To induce neutralizing antibodies (humoral immunity), several strategies in the 
generation of vaccines were developed (Fig. 1.3), ideally together with T-cell (cellular 
immunity) responses [72]. 
 
 
Fig. 1.3 Immunization strategies 
 Schematic overview of the basic strategies for immunization against a viral pathogen 
(adapted from [72]). A non-pathogenic but replication-competent virus is generated 
e.g. by mutation (top-left). Subunit vaccines: Antigens of the respective pathogen are 
transferred to another non-pathogenic viral background MVA (Modified Vaccinia 
Ankara virus) (bottom-left). A dead vaccine in its simplest definition is a non-
replicating virus or virus-like particle (VLP) without genome (top-right). Recent 
attempts utilize combinations of antigens as part of a recombinant virus, expression 
plasmids, peptides or proteins (bottom). 
 
Neutralizing antibodies are targeted towards virus envelope structures, and therefore 
inhibit the virus from infecting its target cells. Generally, pathogen-antibody complexes 
can (I) activate the complement system (CDC; complement-dependent cytotoxicity), 
(II) get lysed by natural killer cells (NK-cells) (ADCC; antibody dependent cellular 
cytotoxicity), (III) or get phagocytized or lysed by phagocytes as well as granulocytes 
[73]. In contrast, infected cells display foreign viral peptides in complex with MHC 
class-I molecules and therefore can be targeted by CTL responses. Vaccines based 
on replication competent viruses (Life vaccine) have the advantage to mostly induce 
both humoral and CTL responses [74,75]. To encounter a possible recombination to 
Expression cassette 
Plasmid 
DNA-vaccine Peptide-vaccine Protein-vaccine 
Life vaccine Dead vaccine 
Virus Dead virus or VLP Life-attenuated virus 
Recombinant virus 
(e.g. vaccinia virus) 
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an again virulent virus, modified (attenuated) recombinant viruses were developed. 
Therefore non-pathogen viral vectors (e.g. MVA [76]) were combined with antigens of 
the respective pathogen (subunit vaccine). Dead vaccines, comprising all variants of a 
non-replication competent attempt, makes use of different subunits of a virus and is 
applied as VLP [77], plasmid, peptides or proteins.  
It was demonstrated that plasmid DNA based vaccines elicit low-level, but protective 
immunity against the influenza virus [78,79], a combination with other vectors was 
suggested [80]. Therefore, a consecutive vaccination strategy was developed 
comprising a DNA vaccination that may prime for enhanced responsiveness of a 
following boost using a viral vector. Several combinations consisting of so-called 
prime/ boost regimens are under development and adapted specifically to each 
pathogen [81,82]. 
 
 
1.5 Seeking for HIV-1 vaccines and broadly neutralizing 
antibodies  
Developing a vaccine that is capable of mediating protection against the HI-virus has 
failed until now. Fundamental barriers that have precluded the development of a potent 
vaccine so far, are the exceptional properties of HIV-1 featuring its preferred entry in 
human CD4+ T-cells, building rapidly a persistent reservoir of latently infected cells, 
masking of functional envelope trimers to evade humoral immune responses [40] (see 
1.3) and its rapid mutation rate. The latter resulted in genetic sequence variability that 
is globally classified in different subtypes or clades. In addition to the global evolution 
of HIV-1 that lead to multiple subtypes, the transmitted (founder) virus undergoes rapid 
mutations resulting in multiple closely related genetic variants (quasispecies) within 
each infected individual [83-86]. Since the development of nonhuman primate models 
[87] to examine the effects of vaccine candidates, more than 30 have also been tested 
in human clinical trials [88,89]. These studies included both, replication-competent or 
incompetent viral vaccines containing HIV-1 gene inserts, HIV-1 VLPs, HIV-1 DNA-
vaccines, and soluble HIV-1 proteins and peptides (as described in 1.2), with or 
without adjuvant formulation and with diverse combinations in Prime/Boost regimens 
[8,11,89,90]. The only trial with a positive outcome in reduction of infection rates 
(31%), was the RV144 trial in Thailand [91], using recombinant canarypox-HIV virus 
prime and gp120 envelope protein boost (adjuvant: alum [92,93]). Taken together, 
strategies that have successfully worked for other pathogens have failed to elicit 
similar immunity to HIV-1 infection, so far. Although the exact type needed for an 
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immune response is still not known, it is a wide consensus that an effective vaccine 
will need to induce both, B-cell and T-cell (CD4+ and CD8+) responses [11]. Further 
evidence for the need of a balanced cellular and humoral immune response was 
recently shown by vaccination experiments in rhesus macaques, where one third of 
the vaccinated animals remained virus-free during a repeated low-dose challenge. 
Furthermore, both cellular and humoral immunity has been inversely correlated to the 
degree of protection [94]. 
However, especially an early neutralization of HIV-1, before the infection of target cells 
occurs, seems highly attractive, considering the fact that HIV-1 integrates genetically 
into cells and forms latently infected reservoirs [95-97]. Thus, it is likely that a vaccine 
that induces broadly neutralizing antibodies (bNAbs) in concentrations that effectively 
neutralize HIV-1 of a broad spectrum of clades, can protect from infection as seen in 
nonhuman primate studies [98,99]. Therefore, eliciting bNAbs turns out to be a critical 
and obtainable component for immunization efforts [88]. Recently, multiple screening 
studies revealed several new bNAbs (VRC01 [44,100], PG9 / PG16 [101]) with 
exceptional breadth and potency (i.e. low inhibitory concentration (IC) values) in 
neutralizing HIV (Table 1.1).  
 
Table 1.1 Characteristics of representative types of human bNAbs [11,98]   
 
Antibody Specificity Median IC50 * (µg/mL) 
PGT128 Env glycans associated** 0.02 
2G12 Env glycans 2.38 
PGV04 CD4 binding site 0.20 
VRC01 CD4 binding site 0.32 
b12 CD4 binding site 2.82 
HJ16 CD4 binding site/ DMR*** # 
PG9 Quaternary epitope gp120 0.23 
PG16 Quaternary epitope gp120 # 
2F5 gp41 MPER # 
4E10 gp41 MPER 3.41 
* Mean of IC50 values obtained, using a panel of 162-pseudoviruses representing all major HIV-1 
 subtypes [98] 
** Exact epitope uncertain [98] 
*** Aa D474, M475, R476 of gp120; frequently targeted epitope of neutralizing antibodies [102] 
# Not determined in that study. 
 Highlighted rows separate groups of similar specificities.  
 BNAb references are to be withdrawn from text. 
 
Further findings about novel antibodies (PGT128 [98]) with even higher (up to 10 fold) 
potency than found before, indicate the enormous progress that is made in this 
discipline. Previously to the recent discoveries of quaternary-epitope-specific 
antibodies, there were three distinct structural regions known to be targeted by the 
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widely known bNAbs [11,103]: (I) b12 [104] targeting the CD4 binding site, (II) 2F5 
[105] and 4E10 [106] targeting separate epitopes within the membrane proximal 
external region (MPER) of gp41 and (III) 2G12 [107] targeting a cluster of glycans on 
the gp120 outer domain. Another distinct region of known high immunogenicity is the 
variable loop V3 [108]. Thus antibodies that are directed to epitopes of the V3 region of 
Env (see 1.3) are commonly among the earliest antibody-responses against HIV-1 
infection [109]. Despite high titers of antibodies, which are elicited from the V3 region, 
only few antibodies were found to be of broad reactivity. Interestingly, such antibodies 
are generally poor effectors of neutralization of primary viruses, due to the masking 
[110-112] of V3 epitopes by V1/V2 domains [111] on the native Env trimer, as 
demonstrated by Davis et al. [110]. One among the best characterized antibodies 
directed against a conformation-sensitive epitope [113-115] (core epitope: GPGR) at 
the crown [47] of V3 is the bNAb 447-52D [116-118]. Particularly, the 447-52D 
antibody features cross clade neutralization capacities, even against primary isolates 
[113,119] and is used as part of a prototypical panning procedure during the course of 
this thesis (see 3.3). 
However, one of the main barriers in eliciting adequate antibodies is represented by 
the fact that the structure of an envelope, which is capable of inducing bNAbs, remains 
unknown. All immunization-effort-derived envelope proteins resulted in antibody 
responses towards immunogenic parts of the applied envelope, but with non- or only 
vaccine-specific neutralizing capacities [120], so far. In order to avoid these problems 
and to shift the immune response [108] to an epitope of interest, several approaches 
[121] recently led to promising results. These “reverse vaccinology” [122] -based 
approaches utilized libraries of chimeric envelope sequences [123] or redirected the 
immune response to more efficacious neutralizing regions on the envelope [124,125]. 
In summary, a chimeric gp120 Env construct (ST-008) with improved neutralizing 
antibody responses was identified using rabbits, as demonstrated by Du et al. [123]; 
Multiple heterologous or the complete deletion of the V1 loop dampened the 
immunogenicity of V3 and differentially altered the immunogenicities of several other 
potential epitopes, as shown by Ching et al. [124]; hyperglycosylation of the variable 
loops showed dampening of their immunogenicity in the context of trimeric Env, but not 
to the cost of target epitopes at the CD4 binding site, demonstrated by Selvarajah et 
al. [125].    
Nevertheless, the proof-of-concept for a vaccine that can elicit antibodies with 
sufficient breadth and potency to protect from infection with heterologous clades 
remains out of reach [121]. On the other hand, there are strong hints that mimicking 
the native, viral, membrane-bound, trimeric envelope complex could elicit antibodies 
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against conserved quaternary structures, facilitating an effective neutralization of the 
virus [123,126]. Thus, getting access to an Env-structure reflecting the antibody-
neutralized state in a physiologically relevant context is likely to be required for 
successful vaccine design [35,127]. A technique to identify those membrane-bound 
envelope trimers with enhanced properties for the binding to bNAbs may therefore 
lead to the identification of envelope structures capable of inducing antibodies with 
similar properties [98,101,121,128,129]. 
 
 
1.6 Display technologies 
Available display systems allow the selection of proteins or peptides out of millions of 
candidates and are the methods of choice to identify optimally binding antigen-
antibody complexes. The variety of display techniques reflects the broad benefit and 
potency of display-based screening methods throughout the various fields of 
application. Each attempt of screening has to match its own unique specifications, thus 
comprising multiple strategies of display systems. The most popular technologies are 
phage [130-134] and yeast [135,136] display, but also bacterial [137], mammalian cell 
[138], eukaryotic virus [139-141], ribosome [142,143], mRNA [144-146] and covalent 
DNA [144,147] -display systems have been developed (Table 1.2).   
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Table 1.2 Characteristics of representative types of display systems 
 
Display technique Type of phenotype and 
genotype linkage 
Library specificities Expression 
 
Expression as a fusionprotein 
with a coat protein of the phage. 
The gene is coded on a 
phagemid packaged in the same 
particle. 
Any protein secretable to 
the periplasmic space of 
E.coli. 
Potential size: ∼1011 [148] 
Prokaryotic 
 
Expression in fusion with a cell 
surface molecule encoded on a 
viral genome. The host 
membrane surrounds arising 
viruses. Particles comprise the 
surface protein and the gene 
encoded on the viral genome. 
Various sizes of proteins, 
fully functional, incl. folding 
and modifications in the ER. 
Mammalian cell membrane 
is present. 
Potential size: ∼108 [149] 
Mammalian 
 
Transfection of bacteria with 
library plasmids and expression 
of library proteins in fusion with a 
cell membrane protein.[150] 
Any protein secretable to 
the periplasmic space of 
E.coli. 
Potential size: ∼1011 
Prokaryotic 
 
Expression in fusion with a cell 
surface molecule encoded on 
DNA, which the cell receives in 
order to be transformed.  
Various sizes of proteins, 
fully functional, incl. folding 
and modifications in the ER. 
Surface: Mammalian, cell 
membrane/ Yeast, cell wall. 
Potential sizes: 
∼1010 (Yeast) [135,151,152] 
∼107 (HEK293T) [138] 
Eukaryotic: 
Yeast / 
Mammalian 
(HEK293T) 
 
Stabilization of complexes 
comprising ribosome, mRNA and 
the nascent peptide upon 
termination of elongation using 
Mg2+ concentrations and low 
temperature.[153] 
Methods applied to the 
range from short 
polypeptides up to antibody 
mimicing proteins.  
Potential size: >1013 [153] 
 
Cell-free 
In vitro 
 
A puromycin (P) molecule is 
covalently bound to the 3’ end of 
mRNA via a single stranded DNA 
linker. At the end of the peptidyl 
transferase reaction, P is bound 
to the nascent peptide as if it 
were a tRNA.  
Cell-free 
In vitro 
 
Expression as a fusionprotein 
with the DNA-binding protein P2A 
(phage P2 derived). P2A 
catalyzes a single strand nick and 
covalently binds to the 5’ end of 
the coding DNA strand.[147]  
Applied for antibody 
fragments (scFv). 
Potential size: >1013 [147] 
Cell-free 
In vitro 
 library gene (red) encoded on DNA (black) 
  library gene (red) encoded on RNA (grey) 
  membrane protein/ peptide linker 
 library peptide/ protein 
 
Figures are not depicted in scale 
 
In viral display systems, the most widespread technique is M13-derived phage display. 
Though restricted to the expression capacities of E.coli, screenings can be done in 
vitro bearing the advantage to possibly select against toxoid agents like tetanus toxoid 
[154]. Various therapeutic antibodies against a variety of diseases, as well as the 
Phage display 
Retroviral display 
Bacterial display 
Cell display 
Ribosomal display 
Stalled 
ribosome 
mRNA display 
P 
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DNA-linker RNA 
DNA display 
Covalent 
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bNAb b12 (see 1.5), were discovered using this technology [155]. For a bacterial 
display, proof-of-principle experiments comprising functional enzymes, vaccine 
antigens and polypeptide libraries [156] were successfully realized. However, in 
comparison to the phage-based platform it turns out that phage may be advantageous 
in its performance [157]. 
If eukaryotic properties, such as folding and posttranslational modifications are 
desired, yeast cell-wall surface display can be utilized [152]. Furthermore, several 
mammalian cell-surface display systems, which enable for a membrane-association, 
were developed for various types of cells, like HEK293T [138,139], BHK [158], HeLa 
[159], Jurkat-e [160] or DT-40 (chicken B-cell line) [161]. Retroviruses are among the 
most efficient mammalian viral vectors and are widely used to stably integrate genetic 
information into the genome of mammalian cells [162]. The potential as a vehicle for 
the display of various peptides as well as antibody-fragments and their selection 
against different target molecules has been demonstrated using murine leukemia virus 
(MLV) [163], avian leucosis virus (ALV) [149] and human immunodeficiency virus (HIV-
1) [139].  
Cell-free in vitro display systems (ribosomal-, m-RNA- and DNA-based, see Table 1.2) 
comprise the potential advantage of bearing no limitations in library diversity [153]. 
Additionally, the lack of transfection or infection steps should make these methods 
more amenable for automation processes. The non-dependence on in vivo expression 
also gives rise to screen both with or against toxoid agents, such as antibiotics or 
tetanus toxoid [145,147]. An overriding principle between the different display 
techniques is the linkage of the phenotype and genotype of the individual elements 
within a library of broad diversity (Fig. 1.4). 
 
 
Fig. 1.4   
Display and screening 
Schematic overview of the common 
principle of display and selection 
procedures. A protein or peptide 
(phenotype) is expressed and 
spatially linked with its genotype 
(Display). After a binding step to a 
molecule of interest, followed by an 
appropriate screening procedure, 
interacting partners are enriched. 
Since the phenotype is linked to the 
genotype, genes of selected proteins 
are amplified and analyzed or 
utilized for another selection round. 
 
One of the most utilized examples is given by recombinant antibody libraries that are 
displayed on E.coli bacteriophages and screened towards target antigen binding of 
Selection Display 
Amplification 
Binding 
Phenotype 
Genotype 
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interest by iterative selection rounds (panning-procedure) [134,144,164,165]. Briefly, 
antibody fragments are cloned and expressed in fusion with the coat protein pIII of the 
M13 derived filamentous bacteriophage (phage). During the phage assembly process 
assisted by a helperphage, the fusion proteins as well as single stranded DNA 
encoding for the fusion protein are incorporated into the phage particle. Thus, phage 
produced by E.coli display an antibody-fragment (phenotype) linked to its DNA-
sequence (genotype) [130]. A screening (panning) is applied by an iterative series of a 
phage selection procedure towards a target of interest and the subsequent de-novo 
production of selected phage after the infection of E.coli. Since phage-display is 
working superior for the screening of antibody fragments such as scFv (single chain 
variable fragment), other mammalian proteins, which can not be expressed in E.coli or 
which have to be displayed with native properties in structural, post-translational 
modification, membrane association or folding, demands for a display-system based 
on mammalian cells or viruses [139,140] (see Section 3.1/ 2).    
 
 
1.7 Objective 
Broadly neutralizing antibodies (bNAbs) like those recently discovered by extensive 
screenings [98,100], and the search for a safe, practical and effective vaccine able to 
re-elicit those bNAbs, are among the main HIV-1 vaccine research aims [11,118]. It 
has been suggested that a stable Env variant with a conformational state that allows 
optimal binding of existing bNAbs may be able to elicit complementary antibodies 
[127,166].  
The objective of this study was to develop a lentiviral vector system and suitable 
mammalian display technique that enables screening of trimeric membrane-bound 
envelopes. This necessitated designing and generating a model Env library in order to 
adjust the panning parameters. Furthermore, the developed system should be 
evaluated by bNAb-mediated enrichment of the highest affinity Env variant from the 
model library applied.   
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2. Material and Methods 
2.1 Molecular Biology 
Unless otherwise specified, processing of all tasks was done using common protocols 
of molecular biology or of the respective manufacturers. All DNA constructs and 
oligonucleotides are listed in appendix 5.2. Inserts were generated by PCR, fusion 
PCR or restriction of plasmids. PCR for preparative purposes was performed using 
Finnzymes Phusion polymerase. PCR for analytic purposes was performed with 
Promega GoTaq Green Master Mix. For the restriction of DNA either NEB (New 
England Biolabs) or Fermentas endonucleases were used. Depending on the 
experiment, amplified DNA was purified with purification columns, or by separation on 
a 0.75 - 1 % agarose gel and subsequent gel extraction (Qiaquick). Ligations were 
processed using a three fold molar excess of the insert related to the target vector 
according to the standard protocol of the used QuickLigation Kit from NEB. 
Transformation of chemical- or electro-competent bacteria DH10B or DB3.1 was 
carried out as described in 2.1.5. Plasmids were isolated after growth of bacterial 
cultures in TB medium containing the appropriate antibiotic by alkaline lysis or by 
using Qiagen Plasmid Kits. The purity and concentration of DNA was measured using 
a NanoDrop Instrument. DNA correctness was verified by obtaining restriction 
patterns or by sequencing. 
 
  
Phusion® High-Fidelity DNA Polymerase Finnzymes, F-530  
GoTaq® Green Master Mix Promega, M7112 
QIAquick Gel Extraction Kit Qiagen, 28706 
QIAquick PCR Purification Kit Qiagen, 28106 
QIAGEN Plasmid Midi/Maxi Kit Qiagen, 12145/12165 
QIAamp DNA Blood Mini Kit Qiagen, 51104 
QuickLigation Kit New England Biolabs, M2200 
E.coli DH10B Invitrogen, 18297-010 
E.coli DB3.1 Invitrogen, 11782-018 
TB medium Terrific Broth medium (12 g Bacto tryptone, 24 g 
Bacto yeast extract, 4 ml Glycerol, 100 ml 0.17 M 
KH2PO4 and 0.72 M K2HPO4, adjust to 1L) 
NanoDrop 1000 Thermo Fisher scientific 
Sequencing Service Geneart 
 
2.1.1 Nested PCR 
To amplify small amounts of DNA two PCR reactions were combined. A portion of 5 µL 
of the first reaction serves as template for the second reaction. The second PCR 
amplifies a region within the amplification area of the first PCR. The reactions protocol 
and amounts are given in Table 2.1. 
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Table 2.1 Nested PCR     
PCR 1   PCR 2  
Volume (µL) Material   Volume (µL) Material  
36-X Sterile water   30 Sterile water  
10 HF Buffer   10 HF Buffer  
1 dNTPs 10mM each   1 dNTPs 10mM each  
1.5 DMSO   1.5 DMSO  
0.5 Primer 8H1   1 Primer 5I3  
0.5 Primer 8H2   1 Primer 5I4  
X Genomic DNA   5 PCR 1   
0.5 Phusion polymerase   0.5 Phusion polymerase  
50 Total amount   50 Total amount  
     
Cycler schedule PCR1   Cycler schedule PCR2  
98°C 10 min   98°C 10 min  
98°C 10 sec. "  98°C 10 sec. " 
53°C 30 sec 25x    40x 
72°C 100 sec "  72°C 75 sec " 
72°C 5 min   72°C 5 min  
4°C ∞   4°C ∞  
 
The PCR2 reactions were loaded on a 0,75 % agarose gel, optically analyzed by UV 
light and gel slices containing fluorescent DNA with the length of envelope genes 
(2.2 kb) were excised and purified according to manufactures instructions. Elution of 
DNA was limited to 12 µL Tris buffer to enhance the concentration. The primers used 
in PCR2 contain overhanging sequences recognized by Esp3I followed by NheI (5I3) 
or XhoI (5I4) sites (5.2.1). Inserts equipped with these recognition sites can directly be 
introduced to QL (Quick Ligation) CcdB cloning (2.1.4). 
 
  
UV source 310 nm 
Tris buffer 10 mM Tris HCl, pH 8,5 
PCR reagents Finnzymes, F-530 
dNTPs NEB N0447 
Primer concentrations 10 µM each in Tris buffer 
 
2.1.2 Realtime PCR (RT-PCR) 
To determine the efficiency of a specific PCR reaction a Realtime PCR standard curve 
analysis using a StepOnePlus device with a 5 fold dilution series of genomic or 
plasmid sample DNA was performed according to the manufacture’s manuals 
(Applied Biosystems, Finnzymes). To determine the amount of different envelope 
coding genes in a mixture of DNA, a Realtime PCR reaction containing one specific 
Primer (5.2.1) for each gene to be analyzed was designed. The probe and forward 
primer was designed to bind to all different envelope variants. One reverse primer was 
designed to also match all envelope genes and therefore was used as reference. The 
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amount of the sample DNA varies according to the experimental setting. For both 
SYBR® Green chemistry or probe-based chemistry the manufacture’s reaction 
protocols were used (DyNAmo Kits, Finnzymes). 
 
  
DyNAmo™ Flash SYBR® Green qPCR Kit Finnzymes, F-415  
DyNAmo™ Flash Probe qPCR Kit Finnzymes, F-455  
StepOnePlus™ Real-Time PCR System Applied Biosystems 
 
2.1.3 Reverse transcription (RT) 
To assess the genetic information of transcribed genes a reverse transcription assay 
was used. First, total RNA of transfected or infected cells was extracted using the 
RNeasy Plus Kit (Qiagen) according to the manufacture’s protocol. Subsequently a 
reverse transcription of envelope specific RNA into cDNA was done using the 
QuantiTect Kit (Qiagen) modified from the standard protocol (Table 2.2). 
 
Table 2.2 Reverse transcription (RT) in two reactions 
Reaction 1 (Elimination of gDNA)  Reaction 2 (RT) 
Volume (µL) Material  Volume (µL) Material 
15-x RNAse free water  4 RT Buffer (5x) 
2.5 gWipeout Buffer  1 RT 
x 500 ng total RNA  0.5 Primer 5G5 
15 Total Volume  14.5 From reaction mix 1 
   
Cycler schedule   Cycler schedule 
42°C 10 min  50°C 30 min 
4°C 10 min  95°C 3 min 
   4°C ∞ 
 
To amplify the generated cDNA, portions of the reaction 2 as well as 0.5 µL of the 
reaction 1 as a negative control were applied to a PCR reaction (Table 2.3). 
 
Table 2.3 cDNA PCR reaction 
cDNA PCR mixture  cDNA PCR Cycler schedule  
Volume (µL) Material  98°C 30 sec.  
14,3-x Sterile water  98°C 10 sec. " 
5 HF Buffer  65°C 30 sec. 30x 
0,5 10 mM dNTPs  72°C 45 sec. " 
0,5 Primer 5F3  72°C 10 min  
0,5 Primer 5G5  4°C ∞  
0,2 Phusion 
x Reaction mix 1 or 2  
 
  
RNeasy Plus Mini Kit Qiagen, 74136 
QuantiTect Rev. Transcription Kit Qiagen, 205311 
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2.1.4 Quick Ligation (QL) and CcdB cloning 
For cloning of DNA into plasmids containing the QL extension (see 3.5.1) a combined 
restriction and ligation process was used [167]. The reaction is divided into two steps. 
At first a restriction mixture containing the QL plasmid (containing CcdB marker [168]) 
and the DNA fragment to be inserted (Insert) was incubated in a PCR cycler for 45 min 
at 37°C. Meanwhile a second reaction for the ligation was prepared and subsequently 
mixed with the first reaction mixture. The combined reactions were incubated as given 
in Table 2.4. The final incubation step at 65°C inactivates the enzymes in the reaction 
mixture. 
 
Table 2.4 QL reaction mixture and incubation schedule   
Reaction 1: Restriction mixture  Reaction 2: Ligation mixture 
Volume (µL) Material  Volume (µL) Material 
14-x Sterile water  4 Sterile water 
2 10 x Tango Buffer  3 10 mM ATP 
2 10 mM DTT  1 10 x Tango Buffer 
1 100 ng/µL Target QL Vector  1 10 mM DTT 
X 100 ng Insert DNA  1 T4 Ligase 
1 Esp3I restriction enzyme 
 
QL reaction schedule 
45 min 37°C 
Adding reaction 2  
45  min 25°C 
45  min 37°C 
45  min 25°C 
10  min 65°C 
 
 
2.1.5 Transformation of bacteria 
DNA plasmids were introduced into bacteria by transformation of either chemical- [169] 
or electro-competent E.coli cells. A complete ligation mixture or pure plasmid DNA was 
applied if chemical competent cells were used. Prior to transformation, electro-
competent cells were prepared and divided into 50 µL aliquots and frozen at -80°C 
according to the given protocol (Table 2.5). The cells were slowly thawed on ice, 1-
3 µL of QL reaction mixture were applied and mixed cautiously only by stirring with the 
pipette tip. The mixture of cells and QL reaction was incubated for 1 min on ice, 
subsequently transferred into a precooled cuvette, pulsed with 1.6 kV, 25 µF, 200 Ω 
(GenePulser, BioRad) and immediately transferred into 500 µL 37°C pre-warmed TB 
medium by flushing the medium into the cuvette and pipetting up and down once. The 
bacteria were incubated at 37°C, 600 rpm for 30 min and subsequently plated on a LB 
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Agar plate containing a corresponding antibiotic for the selection of transformed 
bacterial clones. 
 
Table 2.5 Preparation of electro-competent bacteria 
Protocol for the preparation of electro-competent bacteria 
1 Starter culture: 5 mL LB medium was inoculated and incubated over night at 37°C, 220 rpm with 
bacteria (of a glycerin stock). 
 All materials were precooled at 4°C 
2 200 mL LB medium without antibiotics was inoculated with the starter culture to a OD(600) = 0.1 
3 The bacterial culture was incubated at 37°C, 220 rpm until OD(600) reached 0.5 
4 The bacteria were centrifuged at 4°C, 3220xg for 10 min  
5 The supernatant was discarded and the pellet resuspended in 10 mL sterile 7% DMSO 
6 The suspension was centrifuged at 4°C, 2000xg for 5 min 
7 The supernatant was discarded and the pellet resuspended in 5 mL sterile 7% DMSO 
8 Repeat step 6 and 7 
9 The suspension was centrifuged at 4°C, 2000xg for 5 min 
10 The supernatant was discarded and the pellet resuspended in 0.5 mL sterile 7% DMSO 
11 The suspension was frozen in liquid nitrogen in portions of 50 µL 
 
2.1.6 Preparation of DNA using Microtiter plates (MTP) 
For the preparation of 94 separate bacterial clones, an MTP was filled with 190 µL of 
TB medium including ampicillin per well. Bacterial clones were transferred by picking 
with a sterile pipette tip and short stirring in the target well to be inoculated. Once the 
complete MTP was inoculated, it was transferred onto a Microplate shaker, sealed 
with a “breathable seal” and incubated over night at 37°C at 800 rpm. The next day 
the supernatant was discarded after 30 min of centrifugation at 4°C and 3000 x g. The 
pellets were resuspended in 30 µL P1 by shaking the MTP at RT for 5 min at 
1000 rpm. After complete resuspension, 30 µL of P2 was added to each well and 
mixed shortly by shaking at RT, 1000 rpm for 5 sec. and incubated for 3 min at RT. 
Subsequently 30 µL of ice cooled P3 was added to neutralize the lysis and mixed 
shortly by shaking at RT, 1000 rpm for 5 sec. and incubated for 15 min at 4°C. After 
30 min of centrifugation at 4°C, 3000 x g up to 90 µL of supernatant was transferred 
into a fresh MTP by pipetting carefully without disturbing the pellet. 0,7 x volume of 
isopropanol was added and mixed by shaking shortly at 800 rpm. After 30 min of 
centrifugation at 4°C, 3000 x g the supernatant was discarded carefully by overturning 
the plate in one swinging move. The remaining pellet was washed by addition of 
100 µL ethanol (70 %) to each well and shaking shortly at 800 rpm. After 30 min of 
centrifugation at 4°C, 3000 x g the supernatant was discarded carefully by overturning 
the plate in one swinging move and immediately placing the plate onto a tissue without 
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turning the plate in the meanwhile. After 5 min of incubation the dried DNA pellets 
were resuspended by adding 50 µL Tris-Buffer. Concentration of DNA was calculated 
as the mean concentration of three randomly measured wells. 
 
  
Ampicillin concentration 100 µg/mL 
E.coli DH10B Invitrogen, 18297-010 
Microplate shaker IKA, MTS 2/4 
Breathable seal GBO, 676050 
MTP, U-form untreated GBO, 650201 
TB medium Terrific Broth medium (12 g Bacto tryptone, 24 g 
Bacto yeast extract, 4 ml Glycerol, 100 ml 0.17 M 
KH2PO4 and 0.72 M K2HPO4, adjust to 1L) 
P1, P2, P3 Qiagen, 19051, 19052, 19053  
Tris buffer 10 mM Tris HCl, pH 8,5 
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2.2 Protein biochemistry 
2.2.1 p24-ELISA 
The amount of p24 capsid peptide in a cell culture supernatant of HIV-1 infected 
HEK293T cells, was determined by a p24-ELISA. Since p24 is part of the capsid of 
HIV-1, its amount directly correlates to the amount of virus in the solution.   
After 10 min of centrifugation at RT and 500 x g, the supernatant was inactivated by 
adding 0.1 x volume 5 % (v/v) Triton-X-100 in PBS and incubation at RT for 1 h. The 
solution was directly used or stored at -20°C until usage in the ELISA. Since the 
concentration of the solution was unknown, dilutions of 1:10, 1:100, and 1:1000 were 
used. Standard p24 peptide control dilutions were prepared by pipetting eight 1:2 
serial dilutions, starting with 5 ng/µL, that were treated like normal samples in the 
experiment. The ELISA was processed as given in Table 2.6.  
  
Table 2.6 p24 ELISA  
Protocol 
1 Coating: 100 µL of capture antibody solution was added to each well. Incubation over night at 4°C  
2 Washing: ELISA-washer, program p24_3x_A 
3 Capture: 100 µL of sample solution was added to each well. Incubation for 1 h at 37°C  
4 Washing: ELISA-washer, program p24_6x_A 
5 Detection: 100 µL of secondary antibody solution was added to each well. Incubation for 1 h at RT 
6 Washing: ELISA-washer, program p24_10x_A 
7 Detection: 100 µL of Streptavidin-HRP solution was added to each well. Incubation for 30 min at RT 
8 Washing: ELISA-washer, program p24_10x_A 
9 Signal processing: 100 µL of TMB solution was added to each well. Incubation for 5 min at RT 
10 Reaction stop: 50µL of H2SO4 solution was added to each well. 
11 Measuring: The signals were detected as the absorption at 450 nm 
  
The p24 concentrations for the samples were calculated in relationship to the values 
from the standard curve (standard curve: absorption/concentration, fitted curve in 
linear range, correlation coefficient: R2 > 0,99). 
 
  
Coating buffer 100 mM NaHCO3, pH 9.5 
p24  Stock solution: 50 ng/µL 
Capture solution M01- antibody,1:1000 in coating buffer, Polymun 
AB006 
PBS 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 
1.47 mM KH2PO4, pH 7.4  
BSA AppliChem, A1391 
Blocking buffer PBS, 1 % (w/v) BSA 
Secondary antibody 37G12 antibody biotinylated, 1:5000 in blocking 
buffer, Polymun AB005 
Streptavidin-HRP solution Streptavidin-HRP 1:10000 in blocking buffer, 
Roche 11089153001 
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HEK293T Ad5-transformed embryonic kidney fibroblast cell 
line (ATCC CRL-11268) 
FCS GIBCO, 10270-106  
Pen/Strep 10000 U/ml Penicillin, 10 mg/ml Streptomycin, 
PAN Biotech P06-07100 
DMEM medium DMEM (Invitrogen 41966) + 50 ml FCS, 5 ml 
Pen/Strep 
ELISA plate Maxisorp, Nunc 442404 
ELISA washer Hydroflex, Tecan  
 Wash buffer (WB): PBS 0.05 % (v/v) Tween-20 
Programs: 
- Aspiration 
- Dispensing: 300 µl WB each Well, 300 µl/s 
- Continuous washing with (400 µl/s): 
 1 ml WB program p24_3x_A 
 2 ml WB program p24_6x_A 
 3 ml WB program p24_10x_A 
        2x 3 ml WB program p24_20x_A 
- final aspiration 
TMB solution 20 x volume A + 1 x volume B mixed before use: 
A: 30 mM Kalium-Citrat, pH 4.2 
B: 10 mM 3,3’,5,5’ - tetramethylbenzidine, 
 10 % (v/v) Acetone, 90 %  (v/v) Ethanol, 
 80 mM H2O2 
 
2.2.2 Virus binding assay 
To capture viruses with high affinity to specific antibodies immobilized on MTPs, a 
virus binding assay comparable to ELISA was established.  
 
Table 2.7 Virus binding assay 
Protocol 
1 Coating: 100 µL of capture antibody solution was added to each well. Incubation over night at 4°C  
2 Washing: ELISA-washer, program p24_3x_A 
3 Blocking: The wells were completely filled with DMEM for 2 h at RT 
4 Washing: ELISA-washer, program p24_3x_A 
5 Capture: 100 µL of virus sample solution was added to each well. Incubation for 2 h at RT.  
6 Washing: ELISA-washer, program p24_3x_A using PBS 
7 Lysis: 100 µL of lysis solution was added to each well. Incubation for 1 h at RT 
8 The lysed mixture was treated as a sample in a p24-ELISA as described in 2.2.1. 
 
  
Coating buffer 100 mM NaHCO3, pH 9.5 
Capture antibody solution 10  µg/mL in coating buffer, broad neutralizing 
antibody depending on the experiment 
Blocking buffer DMEM, 10% FCS 
MTP Maxisorp, Nunc 442404 
ELISA washer Hydroflex, Tecan  
 Wash buffer (WB): PBS, 0.05 % (v/v) Tween-20 
Program: 
Aspiration 
Dispensing: 300 µl buffer each Well, 300 µl/s 
Continues washing with (400 µl/s): 
  1 ml buffer program p24_3x_A 
  final aspiration 
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2.3 Cell biology 
2.3.1 Cultivation of cell lines 
Eukaryotic cells were cultivated at 37°C and 5 % CO2 according to common protocols. 
Adherent HEK293T cells were split in a ratio of 1:10 at day 2-3 of cultivation by 
washing once with PBS, detaching with Trypsin-EDTA solution and subsequent 
resuspension of 1/10 of the cells with DMEM to avoid complete confluence. 
 
  
HEK293T Ad5-transformed embryonic kidney fibroblast cell 
line (ATCC CRL-11268) 
PBS 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 
1.47 mM KH2PO4, pH 7.4  
FCS GIBCO, 10270-106  
Pen/Strep 10000 U/ml Penicillin, 10 mg/ml Streptomycin, 
PAN Biotech P06-07100 
DMEM medium DMEM (Invitrogen 41966) + 50 ml FCS, 5 ml 
Pen/Strep 
Trypsin-EDTA Pan Biotech, P10-023500 
 
2.3.2 Transfection 
DNA was introduced into eukaryotic cells using a common transfection protocol [170]. 
Shortly, HEK293T cells were seeded to reach 80% confluence on the day of 
transfection. Therefore, 5 x 105 cells in 2 mL DMEM medium were seeded into a 6-well 
plate the day before transfection. Directly before transfection, the medium was 
replaced by 1 mL of DMEM without supplements and incubated as before until 
transfection. A transfection mixture was prepared by diluting 2 µg of DNA into 100 µL 
DMEM without supplements, adding 8 µL PEI solution and incubation of 10 min at RT 
after vigorously mixing on a vortex instrument. The prepared mixture was pipetted to 
the cells by lifting the plate on one side and releasing the mixture directly below the 
surface of the medium, mixed by swirling and incubated for 6 h before the medium was 
replaced by 2 mL DMEM. After 24 to 72 h the cells or the supernatant were harvested. 
If smaller or greater vessels were used, the amount of cells, DNA, PEI and the amount 
of medium were scaled in relation to the surface of the vessel. 
 
  
PEI solution Polyethylenimine in sterile water at 1 mg/mL 
FCS GIBCO, 10270-106  
Pen/Strep 10000 U/ml Penicillin, 10 mg/ml Streptomycin, 
PAN Biotech P06-07100 
DMEM medium DMEM (Invitrogen 41966) + 50 ml FCS, 5 ml 
Pen/Strep 
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2.3.3 Virus production 
Transfection (2.3.2) of either proviral plasmids, or a three-component (5.2.2/3) 
plasmid mixture (i.e. plasmids for: packaging / envelope / VSV-G) into HEK293T cells 
initiated production of viruses. HEK293T cells were transfected in a 15 cm dish 
according to the protocol given in 2.3.2. After 72 h of incubation the supernatant was 
cleared by centrifugation at 4°C, 3000 x g for 15 min, and transferred onto a 30% 
sucrose cushion by pipetting the sucrose solution carefully below the supernatant. 
After ultracentrifugation at 4°C, 100000 x g for 2h the pellet was resuspended in 
300 µL of DMEM medium over night at 4°C and stored in 50 µL portions at -80°C. The 
amount of p24 was measured by a p24 ELISA (2.2.1).  
 
  
Ultracentrifuge BD, Optima L90K 
Centrifuge tubes BD, 326823 
Plasmid mixture Total amount 30 µg DNA 
Ratio: 
 4 parts pTN-pack  
 3 parts pQL 
 1 part pVSV-G 
DMEM medium DMEM (Invitrogen 41966) + 50 ml FCS, 5 ml 
Pen/Strep 
 
2.3.4 Infection and multiplicity of infection (MOI) 
The day before infection 13 x 106 cells in 30 mL DMEM medium were seeded into 
15 cm dish, or 2.5 x 104 cells in 0.5 mL into each well of a 6-well plate. Directly before 
infection the medium was replaced by freshly prepared 20 mL, or 0.5 mL, DMEM 
containing 10 µg/mL Polybrene. Virus was thawed slowly on ice or used directly after 
production (2.3.3). Various amounts of virus were pipetted to the cells depending on 
the experiment by lifting the dish or plate on one side and releasing the virus directly 
below the surface of the medium, mixed by swirling and incubated for 24 h before the 
medium was replaced by 30 mL or 0.5 mL fresh DMEM medium. The cells were 
assayed 48 h after infection. If cells were transduced using low MOI amounts of virus, 
MOI was deduced by infection of cells (2.3.4) with different amounts of virus and 
counting for GFP positive cells after 48 h post infection using FACS analysis (2.3.6) in 
relation to the volume of virus applied. MOI was estimated to be in a range of highest 
probability for singly infected cells (low MOI: < 0.2) by correlating the measured 
infection rate (% positive cells) and the expected multiplicity of infection (MOI) 
according to the Poisson distribution (5.3). Briefly, at MOI 0.2 the probability (P(n)) that 
a cell is infected by 0 (n) virus is 81.87 % (the negative cells). The rest of the cells are 
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infected by 1 (n) virus 16.37 %, 2 (n) viruses 1.64 % and so on. Therefore, most cells 
getting infected at MOI < 0.2 are singly infected cells. 
 
  
DMEM medium DMEM (Invitrogen 41966) + 50 ml FCS, 5 ml 
Pen/Strep 
Polybrene 10 µg/µL Hexadimethrine bromide in sterile water, 
Sigma H9268 
 
2.3.5 HIV replication assay  
Manipulations in the viral genome of HIV-1 were proven not to affect the functionality 
of essential viral mechanisms by a comparison of the replication potency to its 
predecessor. Because the HIV-1 viruses tested in this assay were in general infection 
incompetent for the targeted HEK293T cells they had to be pseudotyped by an 
heterologous envelope which mediates the infection. The envelope of vesicular 
stomatitis virus (VSV-G) [171] was used to produce a pseudotyped batch of viruses. 
Since VSV-G is a superior envelope for mediating infections, it is known to be toxic if 
constitutively expressed by HEK293T cells [172]. Another envelope glycoprotein, the 
one of baculovirus Autographa californica (gp64) is described [173] to also mediate 
infections in HEK293T cells, but not to be toxic in those cells [172]. A constitutive 
expressing stable HEK293-wtgp64 cell line was kindly provided by S.Bredl. HEK293-
wtgp64 and HEK293T (negative control) cells were seeded in equal amounts and were 
infected with VSV-G pseudotyped viruses at an MOI of 0.1 (2.3.4). At different time 
points, 90 µL of supernatant were collected from each infected dish and analyzed in a 
p24-ELISA for the release of new viruses (2.2.1). Fresh DMEM medium was added to 
compensate for volume changes of the supernatant in every dish. 
 
  
Flp-In-293 Invitrogen, R750-07 
VSV-G Envelope glycoprotein of vesicular stomatitis virus  
gp64 Envelope glycoprotein of baculoviruses 
HEK293-wtgp64 HEK293 FlpIn cell line constitutively expressing 
wtgp64 from its integration site (FRT). 
DMEM medium DMEM (Invitrogen 41966) + 50 ml FCS, 5 ml 
Pen/Strep 
Polybrene 10 µg/µL Hexadimethrine bromide in sterile water, 
Sigma H9268 
 
2.3.6 MACS sorting 
Cells were detached with PBE and centrifuged at 300 x g for 5 min at 4°C. Preparation 
for MACS sorting was done according to Table 2.8.  
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Table 2.8 MACS sorting  
Protocol 
1 Binding: incubation with 10 µg/mL 447-52D antibody diluted in PBE for 1 h at 4°C  
2 Washing: 2 x with 1 mL ice cold PBE, centrifugation at 300 x g for 5 min at 4°C 
3 Capture: 20 µL magnetic beads added to 80 µL resuspended cells in PBE for 15 min at 4°C 
4 Washing: 2 x with 1 mL ice cold PBE, centrifuged at 300 x g for 5 min at 4°C 
5 Staining: incubation with 1:500 anti-human-IgG antibody conjugated with APC in PBE 
6 Washing: 2 x with 1 mL ice cold PBE, centrifuged at 300 x g for 5 min at 4°C 
7 Cells were suspended in 500 µL PBE and applied to separation according to manufacture’s protocol 
8 Columns: Preparation of MS columns according to manufacture’s protocol 
9 Elution: Flush out cells with 1 mL PBE by firmly applying the plunger, supplied with the column. 
 
  
PBE PBS + 0.5 % FCS, 2 mM EDTA, 1 mg/mL NaN3 
Magnetic beads (Mouse anti-human) Miltenyi Biotech, 130-047-501 
MS column Miltenyi Biotech, 130-042-201 
anti-human IgG APC BD, 555787 
 
2.3.7 Flow cytometry analysis 
In flow cytometry, cells are injected in a laminar flow through a capillary and thereby 
scattered to allow a single cell analysis. Passing the measuring system one or more 
beams of laser light of different wave lengths allows a multiparametric analysis of each 
cell according to its shape and fluorescence by various detection units [174,175]. 
Cells were detached with PBE and centrifuged at 200 x g for 5 min at 4°C. Preparation 
for cytometric analysis using FACS Canto II or FACS Aria is shown in Table 2.9.  
 
Table 2.9 Flow cytometry  
Protocol 
1 Binding: incubation with primary antibody diluted in PBE at 4°C  
2 Washing: 3 x with 1mL ice cold PBE, centrifuged at 200xg for 5 min at 4°C 
3 Staining: incubation with secondary antibody diluted in PBE for 1 h at 4°C 
4 Washing: 3 x with 1mL ice cold PBE, centrifuged at 200xg for 5 min at 4°C 
5 Cells were suspended in PBE and subjected to cytometric analysis 
 
   
FACS Canto II and FACS Aria Becton Dickinson (BD) 
PBS + 0.5 % FCS, 2 mM EDTA, 1 mg/mL NaN3 PBE 
   
Primary antibodies:     
447-52D  0.001 - 10 µg/mL, 
60 - 15 min, 4°C 
Polymun, AB014 
5F3 5 µg/mL, 1 h, 4°C Polymun, AB010 
2G12  10 µg/mL, 1 h, 4°C Polymun, AB002 
4E10 10 µg/mL, 1 h, 4°C Polymun, AB004 
HJ16 10 µg/mL, 1 h, 4°C Corti et al. [176] 
Secondary antibody:   
anti-human-IgG PE / APC 1:500, 1 h, 4°C Jackson, 109-136-098 
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2.3.8 FACS (fluorescence activated cell sorting) 
Cells were prepared according to the protocol given in 2.3.7 but finally resuspended in 
1mL PBE per one 15 cm dish and filtered with a 30 µm pre-separation filter. Cells 
were subjected to cytometric sorting by a FACS Aria instrument. The instrument was 
set to “single cell mode” to obtain the most accurate counts for the sorting procedure 
(see 3.3.). In this mode drops containing two target events are discarded. When a 
particle is detected matching the criteria for separation, an electrical charge is applied 
just as the droplet containing this particle breaks off from the stream. As the charged 
droplet passes strongly charged deflection plates, it can be separated and collected 
[177,178]. The genomic DNA of the sorted cells and a portion of cells before sorting 
were prepared according to the manufacture’s instructions but without addition of 
carrier DNA and limited to 20 µL Tris buffer for elution to increase the DNA 
concentration. To amplify viral integrated envelope genes (2.3.4) the genomic DNA 
was used as a template for Nested PCR (2.1.1). 
 
  
PBE PBS + 0.5 % FCS, 2 mM EDTA, 1 mg/mL NaN3 
447-52D 0.2 µg/mL, 15 min, 4°C 
Polymun, AB014 
anti-human-IgG APC 1:500; Jackson, 109-136-098 
Pre-Separation Filters Miltenyi Biotech, 130-041-407 
FACS Aria Becton Dickinson (BD) 
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3. Results 
3.1 HIV-1 envelope display and panning 
The objective to identify an effective immunogen against HIV-1 is one of the biggest 
challenges in the global scientific community as discussed in detail in the introduction 
(1.1-4). One way to identify a to date unavailable immunogen against HIV-1 might be 
the screening for a native and trimeric envelope with strong binding capabilities 
towards an existing bNAb [101,123,128,129]. The display of envelopes on a cellular 
membrane is a further step to its native appearance. In the following experiments a 
procedure to display native, trimeric and membrane-associated envelopes as 
prerequisite for the selection of binding (panning) with high affinity towards applied 
bNAbs is described.  
 
3.1.1 General display and panning strategy for HIV envelope libraries 
Since HIV-1 envelopes should not only be expressed natively and trimeric, but also 
displayed on a eukaryotic cell membrane a direct adaptation of existing panning 
methods was not possible, since the Lentivirus display of Taube et al. [139] was not 
present at the beginning of this thesis. However, the overall principle of panning 
procedures like phage display and others remains the same: The phenotype of a 
library has to be linked to its genotype and somehow displayed towards a binder-
molecule. The resulting binder-molecule / library-binding-partner complexes have to be 
selected in a way that the genotype of the selected binding partner can be amplified. 
With iterative rounds of selections strong binding partners can enrich and are identified 
by poly- and monoclonal screening assays (Fig. 3.1).  
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Fig. 3.1 General panning procedure 
 Schematic overview of the basic principle of the panning methods of this study. An 
envelope is displayed in its native, trimeric, membrane bound form. The particle 
contains the genetic information of the envelope displayed (top). A broad neutralizing 
antibody (bNAb) is incubated together with the displayed envelopes (right). Bound 
antibody-envelope complexes are isolated (e.g. immobilizing the antibodies and 
wash away unbound envelopes) (bottom). Isolation and amplification of the enriched 
genetic information by standard molecular biology techniques (left). Characterization 
of the enriched envelopes with either poly- or monoclonal analysis techniques such 
as sequencing, ELISA or FACS (bottom left). 
 
Based on those common rules for panning, a procedure that includes proposed 
prerequisites for an optimal envelope presentation, as well as the use of bNAbs was 
developed in several steps. 
 
3.1.2 Summary 
Based on recent findings and insights into characteristics of broadly neutralizing 
antibodies and their capabilities to mediate protection against HIV-1 infections, a 
strategy is proposed to screen for optimal HIV-1 envelope binding partners against 
bNAbs. Recent findings of bNAbs restricted to trimeric envelopes [98,101] suggests 
that a native membrane-bound trimeric HIV-1 envelope with high affinity toward bNAbs 
might be a good vaccine candidate.  
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3.2 All in One (AIO) viral display and panning 
Choosing HIV-1 viruses as a vector equals the criteria of a native display of envelopes 
the most, because the viral particles are the native environment of the envelopes in 
vivo. Since very productive display strategies exists (e.g. phage display) [165] that 
make use of a viral vector which carries both the phenotype and genotype of a protein 
library, it was straight-forward to choose a similar system for HIV-1 envelopes. Taking 
only one construct encoding for both, a heterologous Env and the components to form 
a functional HIV-1 particle, the approach was called “All-in-One“ or short “AIO”.    
    
3.2.1 AIO display and panning procedure 
Referring to the well established phage display technologies [130,179] a procedure 
based on HIV-1 viral particles, instead of phage, and HEK293T cells, instead of 
bacteria, was intended. Hence, an HIV-1 based display and panning procedure similar 
to the existing ALV (avian leukosis virus) display of Khare et al. [140,149] (see 1.6) 
was designed  (Fig. 3.2).  
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Fig. 3.2 Schematic overview of the AIO display and panning procedure 
 Starting on the left, HEK 293T wtgp64 cells are transfected with lentiviral vector 
based constructs (i.e. AIO). The produced virus is pseudotyped with wtgp64 and 
displays envelopes of the library. The linkage between genotype and phenotype is 
not given initially (“unlinked” virus library). By low MOI infection of new cells, a 
linkage between genotype and phenotype is achieved for the infected cells. The virus 
formed by these cells is pseudotyped with wtgp64 and displays the envelope coded 
in its genome (top). Broadly neutralizing antibodies (bNab) immobilized on a 
microtiterplate are used to bind virus-displaying envelopes of interest (upper right). 
The envelopes with the highest affinity to the bNab are selected by a stringent 
washing procedure (lower right). The bound viruses are used to infect fresh 
HEK293Twtgp64 cells with low MOI and / or are lysed to perform multiple analyses 
(bottom left). If fresh cells are infected, an enriched virus library is produced and 
another round of selection starts. 
 
The procedure design comprises several steps starting with the production of HIV-1 
virus particles by transfection of HEK293T-wtgp64 cells constitutively expressing 
wtgp64 [180] with proviral DNA. The wtgp64 envelope glycoprotein of the baculovirus 
Autographa californica was chosen, as it is known to mediate infection into 293T cells 
and concurrently not to be toxic (see 2.3.5). The virus particles pseudotyped with 
wtgp64 are used for a low MOI (multiplicity of infection) infection of fresh cells to 
achieve a linkage between genotype and phenotype through infection of only one virus 
per cell (see 5.3). Viruses budding from low MOI infected cells are called “linked” virus. 
A broadly neutralizing antibody (bNAb) is coated on a microtiterplate to bind virus 
particles applied. After several washing steps the remaining virus is either used for low 
MOI infection of fresh cells to start another round of selection or analyzed after lysis by 
p24 ELISA or sequencing.  
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3.2.2 Construction of pTN-AIO and pTN-AIOHSA plasmids 
For the construction of a viral vector with a unique cloning site for the insertion of 
different envelope genes (library), the context of an envelope-deficient NL4-3 derived 
HIV-1 provirus was chosen. This initial construct is called pTN7-Stop (kindly provided 
by Dittmar et al.) and bears the marker gene Renilla Luciferase (R.Luciferase) at the 
position of Nef which is therefore substituted [181,182]. In earlier publications [183] it 
was shown that the substitution of Nef by a reporter gene leads to functional, 
replicating viruses. The plasmid pTN7-Stop was further modified by K.Schilling with a 
G7069C mutation to leave a unique KpnI site 3’ of R.Luciferase [184]. This plasmid 
was chosen as a starting construct (Fig. 3.3).  
 
Fig. 3.3 Schematic overview of the construction of pTN-AIO and pTN-AIOHSA 
 The plasmid pTN7-Stop was used as starting construct. By PCR amplification 
between NheI and NcoI another unique restriction site and a Kozak consensus 
sequence were integrated as illustrated by the scheme. The resulting construct was 
termed pTN-AIO. Another marker gene (HSA) was inserted into the ORF of Vpr by 
PCR modification. The resulting construct was named pTN-AIOHSA. Screening of 
envelope libraries was proposed by replacing the R.Luciferase gene by envelope 
genes. 
 
The unique restriction sites flanking the R.Luciferase were intended to become the 
integration sites of the envelope library. Thus, another unique restriction site, FseI, was 
introduced 5’ of NcoI and the integration of a Kozak consensus sequence was done to 
enhance the expression [185] of a prospective library represented by the R.Luciferase 
reporter gene (data not shown). Since all components necessary for the formation of 
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an enveloped virus, packaged with its genome, were encoded on one proviral 
construct, the resulting vector was called pTN-All-in-One (pTN-AIO) (Fig.3.3). Through 
the integration of FseI, it was also possible to introduce a series of enhancer or 
promoter sequences 5’ of the R.luciferase gene. However, no further increase of the 
expression rates of either R.luciferase or envelopes integrated were achieved (data 
not shown). After integration of an envelope, the substituted marker would not be 
available anymore. To probe for successfully transduced cells after infection (needed 
to determine, e.g. low MOI) another marker gene (HSA) was integrated into the ORF 
of Vpr and therefore substituted it, as described by Ali and colleagues [186,187] and 
the resulting virus was termed pTN-AIOHSA.  
3.2.3 Characterization of pTN-AIO- and pTN-AIOHSA-based viruses 
The small (231 bp) murine heat stable antigen (HSA) intended to be present on the 
surface of pTN-AIOHSA transfected cells and was efficiently detectable with an anti-
HSA antibody in flow cytometry (Fig. 3.4 A). The viruses produced with pTN-AIO and 
pTN-AIOHSA were tested for replicative capacity in comparison to its predecessor 
pNL4-3 (Fig. 3.4 B) by measuring particle release over time with p24-ELISA. 
 
A 
 
B 
!
Fig. 3.4 Characterization of virus variants 
 The functionality of the reporter HSA as well as the replication capacities of the 
virus variants was tested. All results are given as the mean of two independent 
experiments. A Equal amounts of HEK293T cells (5 x 105) were transfected with 
2 µg of the indicated provirus. The cells were stained with anti-HSA-PE antibody 
and probed for HSA expression by FACS, 24 h and 48 h post transfection. B 
HEK293T-wtgp64 cells (5 x 105), which constitutively express wtgp64 envelopes, 
were infected with equal amounts (MOI 0.1) of the indicated viruses. Replication 
was assayed every 24 h by measuring the p24-amounts in the supernatant. !
HEK293T cells transfected with pTN-AIO showed for both, 24 h and 48h after 
transfection, only background levels of HSA positive cells, similar to an un-transfected 
control of 293T cells. Whereas, pTN-AIOHSA transfected cells were approximately 
60% positive after 24 h, and 90 % positive after 48h post transfection (Fig. 3.4 A). 
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NL4-3, AIO or AIOHSA infected cells, revealed no differences in the particle release 
between the respective virus derivatives (Fig. 3.4 B).     
In conclusion, the specific detection of pTN-AIOHSA positive cells as well as similar 
viral replication capacities of AIO and AIOHSA compared to the predecessor NL4-3 
virus was demonstrated.  
 
3.2.4 Binding assay to quantify the amount of viruses captured by bNAb  
To establish the AIO panning procedure, parameters were optimized for antibody 
coating, virus capture and washing procedures. Both magnetic beads and 
microtiterplates were evaluated as solid phase for antibody immobilization. Eventually, 
Nunc-Maxisorp microtiter plates performed best in specifically capturing bNAbs. The 
coating conditions of the antibody were tested concerning the composition of buffers 
and antibody concentration. The best results were obtained using 100mM NaHCO3 pH 
9.5 as coating buffer and 10 µg/mL (1µg/well) of antibody. Furthermore, the best 
conditions for viral incubations were 200 ng/well of virus, 2 h incubation time at room 
temperature and 3 washing steps (see Fig. 3.5). The various conditions tested (data 
not shown) are summarized in Table 3.1.  !
Table 3.1 Parameters tested to capture virus by bNAbs.    
 
Parameter Values tested Optimal values 
Plate type Nunc Maxisorp, Nunc untreated (with 
magnetic beads) 
Nunc Maxisorp 
Solid phase plates, magnetic beads plate 
Coating direct coating of bNAb, pre-coating with 
anti-human IgG, use of protein-G 
magnetic beads 
direct coating 
Coating buffer 100mM NaHCO3 pH 9.5, 50mM 
NaHCO3 pH 9.5, PBS pH 7.0 
100mM NaHCO3 pH 9.5 
Capture antibody 
concentration 
2, 5, 10 µg/mL 10 µg/mL (1µg/well) 
Virus concentration 50, 150, 200, 300 ng/well 200 ng/well 
Virus incubation time 1, 2, 4 h 2 
Virus incubation 
temperature 
4°C, RT, 37°C RT 
Number of washing steps 3, 6, 10 3 
 
The bNAb 2G12 [188] was chosen to optimize parameters of capturing viruses to 
antibodies immobilized on a microtiterplate. Probing for the amounts of virus captured 
by 2G12, a binding assay (see 2.2.2) was performed using the optimal parameters 
found (Table 3.1). The NL4-3 virus was used for a proof-of-concept because of its 
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known binding properties towards 2G12 antibody [189]. The amount of captured virus 
was analyzed by p24-ELISA for two different amounts of virus applied (Fig. 3.5). !
 
Fig. 3.5  
Binding assay  
A proof-of-concept for the binding and recovery of viruses 
was performed by using NL4-3 virus and 2G12 antibody. 
The results are given as the mean of two independent 
experiments. In order to capture virus, 2G12 was coated 
on a Maxisorp plate. NL4-3 viruses were applied to get 
captured by the immobilized antibody 2G12. After washing 
steps, the bound virus was lysed and applied to an ELISA 
assay to probe for the recovered amount of viruses. The 
amounts are shown in ng (p24) normalized to the amount 
of unspecific bound virus.      
 
The loss of viruses applied was between 98 – 99 ± 0.5 %. This nearly complete loss of 
virus could not be prevented by any means in the binding assays done. We usually 
found 5 x 103 transforming units (TU) / ng p24 within our NL-43 virus preparations, 
which is within a common range of values found in the literature [190]. Since the virus 
particles in a binding assay are subject to different incubations and washing steps, a 
further decrease of infectivity was expected. At this stage of development, the decision 
was made to not pursue the AIO virus based panning strategy any longer, but to focus 
on transduced cells for displaying membrane-coupled envelopes.  
 
3.2.5 Summary 
The principle of a panning procedure using complete HIV-1 particles was designed. 
Replication competent NL4-3 derived virus derivatives AIO and AIOHSA were 
constructed and tested. Antibody immobilization and virus capture parameters were 
evaluated. A proof-of-concept using immobilized bNAb 2G12 and HIV-1 NL4-3 virus in 
a binding assay led to unsatisfactory amounts of recoverable virus. Thus a panning 
concept based on cellular display of envelopes was designed (see 3.3).  
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3.3     Construction of an HIV-1 envelope V3 Library  
The development of a display and panning method prerequisites an environment of 
defined parameters. On the basis of a library of few, well characterized envelope 
proteins with known affinities towards the V3-binding antibody 447-52D [113,117,191], 
parameters for a successful display and panning were explored. To avoid selection-
preferences that result from other origins than the binding toward the bNAb, a non-
binding envelope of HIV-1, 96ZM651 (Accession number: AF286224) [192] was 
chosen as backbone for substituting the Env-V3 region with those of different 447-52D 
binding HIV-1 isolates [117]. 
  
3.3.1 Cloning of V3 substituted HIV-1 96ZM651 envelope variants 
The DNA sequences resembling complete V3 regions of different HIV-1 isolates were 
adapted to human codon usage and synthesized as oligonucleotides. The plasmid 
pcDNA3.1-96ZMgp145HA (5.2.2) was used as template consisting of a human codon 
adapted gp145 envelope coding region of 96ZM651 extended by an HA tag cloned 
into the MCS of pcDNA3.1(+) (5.2.2). The V3 region of the envelope 96ZM651 was 
substituted by fusion PCR, inserting V3 regions of different isolates (5.2.1). Finally five 
different 96ZM651 based V3 envelope variants were chosen to form a library of 
envelopes that only differ in the small region of V3. The constructs were also cloned 
into the lentiviral QL9 vector system (see 3.5; 5.2.3). The plasmids were validated by 
restriction and sequence analysis (data not shown).  
       
3.3.2 Binding of 447-52D antibody towards V3 envelope variants 
Previously published experiments of Gorny and colleagues [117] determined a 
differential binding of 447-52D towards peptides of the V3 regions of different HIV-1 
clades (Fig. 3.6 A). The differences in binding capacity were the basis for the decision 
to choose these V3 regions to generate a library with discriminable variants (3.3.1). 
After transfection of HEK293T cells with the different V3 constructs and staining with 
447-52D antibody, cells were analyzed by flow cytometry. Un-transfected HEK 293T 
cells were used as negative control (neg.). The mean fluorescence intensity values 
(MFI) were corrected according to different expression levels of envelopes with the use 
of the antibody 5F3 [188], which is targeted towards an epitope not inside the V3 
region. Thus, the epitope is equally available on all constructs used (see 2.3.7). The 
corrected values are shown as % of total MFI. The differential binding of 447-52D 
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antibody towards cell membrane displayed envelope V3 variants is shown in Fig. 3.6 
B. 
  
A 
 
B 
!
Fig. 3.6 Comparison of 447-52D antibody binding towards envelopes displayed on 
eukaryotic cells versus plate bound peptides  
 A V3 peptides of corresponding HIV-1 strains were shown by Gorny and colleagues 
[117] to bind with different relative Kd values. The reciprocal values are given and 
sorted from strong binding to non binding peptides (left to right) B 5x106 HEK293T 
cells were transfected with pcDNA3.1(+) based V3 variant plasmids (2 µg each) and 
stained with 10 µg/mL 447-52D antibody 48 h after transfection. FACS analyses 
were done and the means of three independent experiments are shown. The 
differential binding pattern for the V3 variants is represented by the mean 
fluorescence intensities (MFI) normalized to equal envelope expression by an 
additional staining step with 10 µg/mL 5F3 antibody. Secondary stains were done 
with anti human antibodies coupled with APC or PE. 
 
The obvious differences in binding capabilities in comparison between peptides and 
envelopes displayed on cells were notably distinct. The variant MN showed the 
highest, and SF33 the lowest affinity as demonstrated in both assays. However, 
according to the variants RF, CDC42 and HXB2 the depicted order in decreasing 
binding capacity of the used peptides, is diametrically opposed to the assay using 
envelopes displayed on cells (Fig. 3.6 A/B). Thus, reproduction of the binding-strength 
ranking obtained by the use of peptides was not achieved. It is known that the binding 
towards the linear epitope of V3 is also conformation-dependent [119]. Thus, it is not 
unreasonable to assume that an envelope displayed on a eukaryotic cell is differently 
targeted, than a linear peptide. However, it was not the aim to reproduce the data 
demonstrated by Gorny et al., but to generate discriminable variants of envelopes, 
which forms a feasible test-library for panning procedures.       
 
3.3.3 Summary 
A library of envelope variants differing only in their V3 region was constructed. The V3 
variants were tested for differential binding towards the bNAbs 447-52D with flow 
cytometry after transfection into HEK293T cells. The MN and SF33 variants were the 
strongest and the weakest binding V3 variants respectively, whereas the performance 
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of RF, CDC42 and HXB2 variants differed from the reported experiments made with 
peptides. An envelope V3-variant library with distinct binding strengths toward the 
antibody 447-52D was successfully generated. 
 
 
3.4 Cellular display and MACS-mediated panning 
3.4.1 Cellular display and panning procedure (MACS-panning) 
Any infected cell, from which an HIV-1 virion has been released, originally produces, 
like all other viral proteins, the viral envelopes that are subsequently displayed on the 
virus particle. Thus, after infection of target cells, HIV-1 envelope glycoproteins are 
expressed and displayed on the cellular plasma membrane [14]. Therefore a 
mammalian cell surface display was established to present envelope variants in a 
native, trimeric, membrane-bound environment. Hence, no virus particles were 
involved into the display and selection process itself and were further only used as a 
vector for the transduction of cells  (Fig. 3.7).  
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Fig. 3.7 Schematic overview of the MACS-panning procedure 
 Vectors coding for different envelope variants are introduced into HEK 293T cells 
either by transfection or infection. The linkage between genotype and phenotype is 
only given if the cells are infected by low MOI infection or if the cells are transfected 
separately by each variant (top). Broadly neutralizing antibodies (bNab) are applied 
to bind to cells displaying envelopes of interest (upper right). The envelopes with the 
highest affinity to the bNab are selected by a MACS selection procedure (lower 
right). The bound cells are eluted and lysed to amplify the envelope genes. 
Amplification is either done from mRNA (by RT / PCR) if cells are transfected, or 
from genomic DNA (by PCR) if infected. The recovered envelope genes are cloned 
into an appropriate vector and analyzed by sequencing (bottom left). Fresh cells are 
transfected (together with packaging and VSV-G constructs) to produce virus for low 
MOI infection of fresh cells. Or the vector is used to directly transfect fresh cells and 
enter a new round of selection. 
 
The MACS-panning procedure design comprises several steps starting with either the 
production of HIV-1 virus particles by triple-transfection (envelope expressing-, 
packaging-, VSV-G- plasmid; see 2.3.3) and subsequent low MOI infection or with 
direct transfection of HEK293T cells with envelope expressing plasmids. The linkage 
between genotype and phenotype is reached by low MOI infection (see 5.3). Viruses 
budding from low MOI infected cells are called “linked” viruses. In the case of direct 
transfection, multiple different plasmids are expected to be expressed in one cell, and 
a less strong enrichment is anticipated. A broadly neutralizing antibody (bNAb) is 
applied to the envelope expressing cells to bind towards the envelopes anchored on 
the plasma membrane surface. Those cells expressing envelopes with highest affinity 
towards the bNAb applied are intended to bind more antibodies, thus facilitating 
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selection by a MACS enrichment procedure. After several washing steps the remaining 
cells are eluted and the envelope genes are amplified either from mRNA (RT followed 
by PCR) if cells are transfected, or from genomic DNA (PCR) if infected. The 
recovered envelope genes are cloned into an appropriate plasmid and analyzed by 
sequencing. To begin another round of panning the plasmids are either used to 
produce virus once more, or to transfect fresh cells directly, and another round is 
started. 
 
3.4.2 MACS panning using one binding and one non-binding V3 variant 
A proof-of-concept for MACS-mediated enrichment of envelopes binding towards 447-
52D antibody was done by separately testing the selectivity of the system against 
transfected HEK293T cells expressing the MN (binding) or SF33 (non binding) 
envelope (see 2.3.6). With FACS analysis of collected samples of cells drawn at each 
step during MACS panning (Fig. 3.8 A), the status of enrichment was recorded. 
Samples of cells directly before addition to the columns were analyzed as well as 
samples of the washing fraction (negative) and the finally eluted fraction (positive). Un-
transfected HEK293T cells were used as a background subtraction sample. An similar 
transfection-efficiency (MN = 60 %, SF33 = 55 %) and Env expression-rate (MFI: 
MN = 18, SF33 = 18) was separately determined by staining samples of both MN and 
SF33 transfected cells, with 5F3- and anti-human-PE -antibody respectively (data not 
shown). The MFI of eluted cells transfected with MN more than doubled to 113, 
compared to the sample before enrichment with 46.4, whereas the MFI of cells 
transfected with SF33 stays the same in every sample (Fig. 3.8 B). Only cells 
expressing envelopes that bind towards the applied 447-52D antibody were enriched.   
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Fig. 3.8 MACS-mediated enrichment of envelopes displayed on HEK293T cells  
A Schematic overview of the MACS separation procedure using separately transfected 
HEK293T cells displaying either the MN or SF33 envelope derivate. The cells are first stained 
with 447-52D antibody and subsequently in that order with anti-human magnetic beads and 
anti-human-PE antibody. The enrichment of cells, presenting envelopes with high affinity to 
447-52D, is achieved by the use of magnetic bead separation. Cells bound by the 447-52D 
antibody are also labeled with magnetic beads and are immobilized within a magnetic field. 
After stringent washing steps the magnetic force is removed and cells are eluted. Envelope 
genes of different fractions are recovered and cloned into an appropriate vector, to enter a 
new round of selection by transfecting fresh HEK293T cells. B FACS analysis of separately 
enriched cells using MACS-panning with MN (binding) and SF33 (non binding) displaying cells. 
HEK293T cells (5 x 105) were transfected with pcDNA3.1 -based MN or SF33 constructs (2 µg 
each). A sample of both cells was stained with 5F3 antibody (10 µg/mL). An equally 
transfection efficiency (% positive cells) and Env expression-rate (MFI) was determined, 48 h 
after transfection (data not shown). Remaining cells were equally stained for MACS-panning 
with primary antibody 447-52D (10 µg/mL) and subsequently with anti-human magnetic beads 
and anti-human-PE antibody. Fractions before (grey), negative (blue) and positive (red) were 
collected separately and analyzed by FACS. The envelope expression is illustrated in colored 
histograms representing the MFI (Mean) compared to un-transfected HEK293T cells (black). C 
HEK293T cells (5 x 106) were transfected with pcDNA3.1-based MN or SF33 constructs (10 µg 
each). Cells were mixed 48 h after transfection as indicated. Separate MACS Panning 
procedures for every mixture were performed and fractions were collected as described in (B). 
Cells of each fraction were lysed; envelope genes were PCR amplified and cloned into 
pcDNA3.1. Mixed sequence analysis directed to a distinct sequence range was used to 
monitor the enrichment of envelopes in the different fractions. The chromatograms of the 
sequence range relevant to discriminate between MN and SF33 are shown respectively. 
 
Different amounts of separately transfected and subsequently manually mixed cells 
were screened with MACS-panning. Separate MACS-panning procedures for every 
mixture were performed and fractions were collected as described before.  A sample of 
cells from every fraction was lysed; envelope genes were amplified by PCR and 
cloned into pcDNA3.1(+). A polyclonal sequence analysis tailored to a distinct 
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C G G G G
C G G G G
285 286 287 288 289
1824
0
Fragment
THB55_5
G G G G
G G G G
285 286 287 288
1608
0
Fragment
THB55_6
A A A A
A A A A
283 284 285 286
1957
0
Fragment
THB55_7
C A A A A
C A A A A
284 285 286 287 288
1641
0
Fragment
THB55_8
A A A A
A A A A
283 284 285 286
2275
0
Fragment
THB55_9
C 
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sequence region, which is unique for MN and SF33 was used to monitor their 
enrichment in the different fractions. The relevant unique sequences to discriminate 
between MN and SF33 are shown for every mixture and fraction. Every mixture was 
screened for one round and even with lowest amount of MN (10%) the sequence 
representing MN clearly was enriched demonstrated by the sequence switch from 
GGGG (SF33) to AAAA (MN) (Fig. 3.8 C). !
3.4.3 MACS-panning using the V3 library 
The complete V3 envelope library was screened in MACS-panning with separately 
transfected cells. Equal amounts of 447-52D antibody stained cells of every variant 
were mixed directly before the MACS procedure. After one round of enrichment the 
envelope genes recovered from the eluted cells were cloned into pcDNA3.1(+) and 
DNA was prepared.  The enrichment after one round was determined by sequencing 
one MTP of separately grown bacterial clones (Fig. 3.9 A). The distribution of identified 
clones after one round was similar to the binding strength pattern observed in Fig. 3.6 
B. For a subsequent second round, the cells were no longer separately transfected 
with each V3 variant. Instead of that, the plasmid DNA mixture obtained from the 
pooled bacterial colonies after the first round were transfected directly, in order to proof 
whether a strict phenotype and genotype linkage is still needed. Although representing 
the enrichment status after one round, a further increase of the binding and a decrease 
of the non-binding envelope variants was not achieved by such a second round of 
panning, due to the absence of a linkage between genotype and phenotype (see 1.6). 
Hence, the counts per V3 variant were equally balanced again with only SF33 not 
being subject to any change in amount. The positive trend of enrichment was not 
enhanced, but nearly completely abolished (Fig. 3.9. B).  
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A 
!
B 
!
Fig. 3.9 MACS mediated enrichment of envelopes displayed on HEK293T cells  
 A HEK293T cells (5 x 106) were transfected separately with pcDNA3.1 based 
envelope constructs as indicated (10 µg each). Subsequently the cells were mixed 
together in equal parts of 1/5 and applied to a MACS Panning procedure 48 h after 
transfection. The envelope genes after one round of Panning were amplified from 
mRNA (RT/PCR) and cloned into pcDNA3.1. The DNA was prepared from an 
overnight culture of transformed bacteria. 94 (one MTP) separate clones were 
sequence analyzed, and assigned to the different variants. The relative amount of 
every variant is shown. B The obtained plasmid DNA mixture of part (A) was used to 
enter a second, “unlinked” round of panning by directly transfection of fresh cells. 
Sequence analysis of one MTP plate of bacterial clones after completion the second 
round of panning is shown as the mean of two separate experiments.  
 
The enrichment of binding envelopes (i.e. MN) was only observed as long as separate 
transfections of the V3 variants were done. The intention of a panning procedure, 
however, is to screen libraries of many mixed variants at once (phage display: >109) 
[193]. Using separate transfections at this scale were not feasible. Thus, the possibility 
to obtain a “linked” library, although cells are transduced with a mixture of variants 
directly from the beginning of the panning procedure, was explored.  
Therefore, virus was produced by a “triple-transfection” of a mixture of equal amounts 
of the envelope V3-variants that were cloned into a lentiviral vector (QL1; see 3.5), 
transfected together with packaging and VSV-G plasmids (see 2.3.3). Subsequently, 
target cells were infected with low MOI (0.1) as verified by staining of infected cells 
with 5F3 antibody (data not shown). Equal amounts of infected cells were subjected to 
MACS-panning and the eluted cells were analyzed by sequencing (Fig. 3.10).  
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!
Fig. 3.10 MACS Panning with low MOI infected HEK293T cells  
 Virus, pseudotyped with VSV-G was produced using a mixture of equal amounts of 
QL1 (see 3.5) based envelope V3 constructs (see 2.3.3). HEK293T cells (5 x 105) 
were infected with low MOI (0.1) verified by 5F3 antibody staining (data not shown). 
Subsequently the cells were applied to a MACS Panning procedure 48 h after 
infection. The envelope genes were amplified from the genomic DNA of the eluted 
cells, cloned into pcDNA3.1, sequences were analyzed and assigned to the different 
variants similar to Fig. 3.9.  
 
Neither the MACS-panning using mixed-transfected (Fig. 3.9 B), nor with mixed-virus-
infected cells (Fig. 3.10) achieved an enrichment of the binding envelopes (e.g. MN), 
or a depletion of the non-binding envelope (SF33). Although the low MOI infection with 
mixed viruses should have most likely led to a separate infection of the cells, the 
obtained results differed to an enrichment experiment with separately transfected cells 
(see Fig. 3.9 A). Hence, two possible vulnerabilities of the MACS-panning procedure 
were considered: (I) The calculations to get low MOI infections were done using 5F3 
antibody, binding towards cells that express envelopes. Assuming, that cells get 
infected but remain anyhow inaccessible for 5F3 antibody (weak expression, unusual 
folding or no display of envelopes), some cells would be miss-interpreted as un-
infected cells. This would have caused an underestimation of infected cells and result 
in a higher MOI than desired. Infections with higher MOI are equivalent for having a 
higher probability to get more than one integration event per cell (see 5.3). Multiple 
variants of envelopes per cell were shown to reverse the enrichment effect of binders 
in the MACS-panning (Fig. 3.9 B); (II) Infected cells, that exhibit higher expression of 
envelopes than others, were probably preferentially selected, due to the presence of 
more binding partners towards the applied antibody on their surface. Using a MACS-
based, polyclonal enrichment-process the discrimination between single cells with 
different envelope expression rates is impossible.  
Thus, (I) a marker for infected cells only dependent on successful integration of the 
viral genome is desirable. (II) The selection with MACS columns had to be replaced by 
FACS-sorting that permits for the simultaneously determination of the Env expression 
strength on a single cell basis. Therefore, a new vector system (pQL) was designed 
and established to introduce GFP for accurate measurements of the MOI of infected 
cells (see 3.5).   
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3.4.4 Summary 
The MACS-panning procedure was designed and a proof-of-concept was successfully 
shown for HEK293T cells that were separately transfected. No success in enrichment 
of binding envelopes (i.e. MN) and depletion of non-binding variants (i.e. SF33) was 
observed, when cells were transduced with a mixture of variants. This was also the 
case when “low-MOI conditions” were used to create an effect of separately 
transduced cells. Two weaknesses of the MACS-panning design concerning the 
determination of low-MOI infections and a possible bias towards high envelope 
expressing cells were noticed and reconsidered. 
 
 
3.5 QL vector development  
3.5.1 Design and construction of QL vectors  
As described above, the determination of transduced cells and the accuracy of low 
MOI infection are crucial to ensure a high probability for singly infected cells and a 
linkage of phenotype and genotype. Furthermore, an accurate marker and method to 
control the envelope expression rates of transduced cells is needed. Staining cells with 
5F3 antibody turned out to be neither an accurate marker for infection nor for the 
expression of envelopes, because 5F3 antibody is not binding all infected and 
envelope expressing cells (see Fig. 3.13 B). Furthermore, being addicted to 
appropriate expression and display of envelopes with equal efficiency is a hindrance 
that is immanent to the use of antibodies as a marker. This is especially true if such an 
antibody is expected to bind equally to every envelope in a more complex library. 
Therefore, a new lentiviral vector was designed to overcome this limitation. The 
integration of GFP into the lentiviral part of the plasmids introduced a marker suitable 
for direct identification of infected cells (Table 3.2/ 3).   
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Table 3.2  Components of the lentiviral starting construct  
 The plasmid pWPXLd (Addgene) was used as the starting construct. The construct consists 
of a plasmid backbone (not shown) and carries a lentiviral expression cassette consisting of 
the listed elements. 
Element Properties 
5’LTR Long terminal repeat: HIV-1 regulatory elements, transcriptional control and promoter region [194]. 
RRE 
Comprises parts of the Env sequence encompassing the Rev response element (RRE) 
flanked by splice signals (not shown): Increased packaging of RNA into virions, increased 
transcription and cytoplasmic export of full-length RNA [195] 
EF1α Human elongation factor 1 aplpha (EF1α) promoter [196]: Constitutive promoter less susceptible to down regulation [197,198]  
cPPT Central polypurin tract: Involved in forming a central DNA flap: Increases the transduction efficiency by completing the nuclear import process to wild type levels [195,199]  
GFP Green fluorscent protein and its derivatives eGFP and YFP are used as fluorescence marker genes [200] 
WPRE The posttranscriptional regulatory element of woodchuck hepatitis virus, increases the level of expression [201] 
3’LTR A truncated version of 3’LTR is used resulting in a self-inactivating viral vector (SIN) [202]. !
Furthermore, a CcdB positive selection marker (killer-gene [168]) was integrated to 
enable a convenient and efficient cloning [167] (see 2.1.4) of envelope variants. 
The lentiviral plasmid pWPXLd [203] (5.2.2) was used as a starting construct. Because 
of the presence of Esp3I sites, the original backbone of pWPXLd was substituted by 
non- Esp3I containing plasmid backbones, PCR-Script-Amp (5.2.2) with its derivatives 
pQL1-5, as well as by pcDNA3.1(+) (5.2.2) with its derivatives pQL6-11 (Table 3.3). ! !
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Table 3.3 Vector pQL: stages of development  
 The eGFP cassette of pWPXLd was substituted by a CcdB expression cassette flanked by 
two Esp3I restriction sites (see Fig. 3.11) enabling for the QL cloning procedure (pQL1/ 6) 
described in part 2.1.4. Besides the integration of the CcdB cloning cassette, several 
attempts were necessary to integrate an again functional expression cassette of GFP or YFP 
using standard PCR and cloning techniques. 
Plasmid Map of the lentiviral part 
pWPXLd 
 
 
Basic lentiviral vector 
pQL1 / 
pQL6* 
 
 
The CcdB cloning element was integrated. *QL1 versus QL6: plasmid backbones were 
switched (not shown/ see main text).  
pQL2 
 
 
An expression cassette consisting of SV40 early promoter and GFP was cloned upstream of 
the 3’ LTR sequence 
pQL3 
 
 
The orientation of the GFP expression cassette was switched compared to QL2 and a sNRP-1 
poly adenylation site [204] was added 
pQL4 
 
 
The same orientation as in QL3, but YFP (Clonetech, see 5.2.2) and a SV40 poly-adenylation 
sequence were chosen 
pQL5 / 
pQL7* 
 
 
IRES (internal ribosome entry site, implemented from pMACS LNGFR-IRES, (see 5.2.2) and 
GFP were introduced downstream of the CcdB cloning site. *switched plasmid backbones (see 
above and main text) 
pQL8 
 
 
An artificial Intron [205] was cloned upstream of the IRES site  
pQL9 
 
 
GFP and CcdB cloning site were switched in positions 
pQL10 
 
 
Equals pQL5/7 except for using IRES2-eGFP from pIRES2-eGFP (Clonetech, see 5.2.2) 
pQL11 
 
 
Equals QL9 except that the TaV p2A peptide [206] substitutes the Intron-IRES 
 
RRE 5‘ LTR cPPT EF1α WPRE eGFP 3‘ LTR 
RRE 5‘ LTR cPPT EF1α WPRE CcdB cloning site 3‘ LTR 
RRE 5‘ LTR cPPT EF1α WPRE GFP P-SV40 CcdB cloning site 3‘ LTR 
RRE 5‘ LTR cPPT EF1α WPRE GFP P-SV40 CcdB cloning site 3‘ LTR sNRP1-pA 
RRE 5‘ LTR cPPT EF1α WPRE YFP P-SV40 CcdB cloning site 3‘ LTR SV40-pA 
RRE 5‘ LTR cPPT EF1α IRES GFP CcdB cloning site 3‘ LTR WPRE 
RRE 5‘ LTR cPPT EF1α IRES GFP CcdB cloning site 3‘ LTR WPRE Intron 
RRE 5‘ LTR cPPT EF1α IRES GFP CcdB cloning site 3‘ LTR WPRE Intron 
RRE 5‘ LTR cPPT EF1α IRES 2 eGFP CcdB cloning site 3‘ LTR WPRE 
RRE 5‘ LTR cPPT EF1α TaV p2A eGFP CcdB cloning site 3‘ LTR WPRE 
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The construction of pQL1 and 6 was sequentially performed by (I) PCR amplification of 
the MCS (multiple cloning site) of pcDNA3.1(+) (primer pair 4A1/1A4) and blunt-end 
ligation with pPCR-Script-Amp linearized with EcoRV. (II) Subsequently, the plasmid 
was linearized with EcoRV/XbaI within the MCS and ligated with the lentiviral part of 
pWPXLd obtained by restriction with SspI/XbaI (5.7 kb fragment). (III) The substitution 
of eGFP within the WPXLd part by a CcdB expression cassette flanked by two Esp3I 
restriction sites, cloned via MluI/NdeI and propagation in DB3.1 bacteria (CcdB 
resistant) resulted in the pQL1 plasmid. The vector pQL6 was constructed by another 
substitution of the plasmid backbone. Here, the lentiviral part of pQL1 (EcoRI; blunt-
ended; 5.4 kb) was ligated with the plasmid backbone of pcDNA3.1(+) (PciI/MfeI; 
blunt-ended; dephosphorylated; 1.9 kb). Particularly, pQL9 was created by cloning a 
GFP gene into the MCS of pMACS LNGFR-IRES (#130-091-887, Miltenyi Biotech) via 
EcoRI/BamHI. Subsequently, an expression cassette consisting of GFP, synthetic 
Intron [205] and an IRES site (internal ribosome entry site) was introduced upstream of 
the CcdB cloning site of pQL6 (via PCR, 8B2 / B3) resulting in the final pQL9 plasmid.  
The elimination of Esp3I sites in the original plasmids enabled the Insertion of a CcdB 
expression cassette with flanking Esp3I restriction sites (Typ IIS) mediating the QL 
cloning procedure [167] (see 2.1.4).  
With the QL cloning procedure the restriction and ligation reactions were performed 
simultaneously in one reaction vessel. A subsequent selection for positively cloned 
plasmids was done by transformation of the CcdB sensitive bacterial strain DH10B 
(Fig. 3.11).  
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Fig. 3.11 Schematic overview of the QL cloning procedure 
 An envelope or envelope library is amplified with primers (see 5.2.1) extending the 
envelope gene by the restriction sites Esp3I followed in 5’3’ by NcoI with the 
forward primer (e.g. 5I3) and XhoI for the reverse primer (e.g. 5I4) (top right). The 
amplified envelope gene and a QL plasmid (e.g. pQL9) are jointly incubated with the 
Esp3I restriction enzyme and T4-Ligase (see 2.1.4). Only the equally colored “sticky-
ends” are compatible and can be ligated successfully (right). After transformation of 
CcdB sensitive bacteria like DH10B, only bacteria bearing a plasmid without CcdB 
are able to form colonies (left). Only few (<0.01%) bacteria are seen on control 
plates where no envelope insert was applied to the reaction due to irregularly ligated 
“empty” plasmids. 
 
As Esp3I cleaves downstream of its recognition site, NcoI and XhoI sites were chosen 
as adjacent restriction sites. After restriction with Esp3I the resulting DNA bears fully 
compatible NcoI and XhoI “sticky-ends” allowing an easy introduction of inserts using 
the QL method (see 2.1.4). With subsequent derivatives of pQL1 and pQL6, envelope 
and GFP genes were introduced differently into the lentiviral part of the vector (Table 
3.3) to achieve both, envelope and GFP expression (3.5.2). 
 
3.5.2 Characterization of the QL vectors 
Multiple derivatives were created and tested to achieve GFP expression in the 
presence and absence of an envelope (MN) expression cassette (Fig. 3.12 A). Cells 
transfected with QL vectors (with and without cloned envelope) that showed GFP 
RRE 5‘ LTR cPPT EF1α IRES GFP CcdB 3‘ LTR WPRE Intron 
Envelope 
Envelope 5’ … CGTCTC C CATGG!3’ … GCAGAG GGTAC C!
Esp3I NcoI 
C TCGAG GAGACG … 3’!
GAGCT C CTCTGC … 5’!
Esp3I XhoI 
CcdB CGTCTC C TCGAG … 3’!GCAGAG GAGCT C … 5’!
Esp3I XhoI 
5’ … C CATGG GAGACG!
3’ … GGTAC C CTCTGC!
Esp3I NcoI 
Transformation of DH10B: 
CcdB 
! toxic 
Envelope 
! non toxic 
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expression and at the same time could be successfully stained with 447-52D antibody 
towards the envelope variant MN, were compared for equal GFP and 447-52D 
antibody signals by FACS analysis (Fig. 3.12 B). 
 
A 
 
B 
!
   !
C 
 
D 
!
Fig. 3.12 Evaluation of the QL vector development  
 A / B HEK293T cells (3 x 105) were transfected with equal amounts (1 µg each) of 
the QL based constructs with or without an MN envelope V3 gene as indicated. 48 h 
after transfection all cells were stained with 50 µL 447-52D (10 µg/mL) and 
subsequently anti-human APC (1:500) antibodies. The cells were analyzed by FACS 
for co-expression of GFP in presence or absences of MN envelope. Values are 
shown as percent positive cells after histogram subtraction of un-transfected 
HEK293T cells (A); Cells that are both positive for GFP and 447-52D staining (B). C / 
D HEK293T cells (3 x 105) were either transfected (1 µg) or infected (MOI 1) with a 
QL9 based V3 envelope construct. The cells were stained with 5F3 (10 µg/mL) and 
anti-human APC (1:500) antibodies, 48 h after transduction. In FACS analyzes the 
cells were probed for GFP and 5F3 expression. The ratio of 5F3 and GFP positive 
cells is indicated.  
 
Only cells transfected with QL9 and QL11 showed GFP expression correlating with the 
expression of the MN envelopes stained with 447-52D antibody. In both plasmids GFP 
is cloned upstream of the envelope gene. In QL9 an IRES site [207], in QL11 a p2A 
peptide [206] is used to couple the expression of GFP and envelope. Since QL9 was 
the first functional vector variant, all following characterizations were based on this 
vector. A QL9-based set of the V3 library envelopes (3.3.1) was compared for GFP 
versus 5F3 antibody binding after transfection, as well as after infection of 293T cells. 
The binding of 5F3 antibody differs between transfection and infection, which is shown 
by the ratio of 5F3/GFP illustrated with the dotted line (Fig. 3.12 C/D). This effect was 
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further analyzed, since 5F3 antibody was used in earlier experiments (3.4) to 
determine positively infected cells and to calculate low MOI. 
 
3.5.3 A marker for transduction and envelope expression  
Since GFP was initially introduced as a marker (3.5.1) only for successful 
transductions, antibodies were explored to serve as a marker for equal amounts of 
envelopes anchored on the plasma membrane of transduced cells. Therefore, 
antibodies were chosen that binds the envelope variants outside of their differing V3 
regions (Fig. 3.13). 
 
A 
 
B 
!
Fig. 3.13 Comparison of antibody binding to MN envelope transfected or infected cells  
 Petridishes with 1.5 x 106 HEK293T cells were either transfected (5 µg; blue) or 
infected (red) with an MOI 0.5 (according to GFP) with QL9-MN, which encodes for 
the strongest 447-52D binding envelope V3 variant MN. Cells were split into four 
portions and stained with 0.5 mL 10 µg/mL primary antibody (i.e. 447-52D, 5F3, 
HJ16) and APC conjugated secondary antibody (1:500) 48 h after transduction. 
FACS analysis is shown for each antibody as positive cells (%) gated in relation to 
un-transduced HEK293T control cells. The factor of reduction (colored numbers) 
between equal cell populations, either A transfected or B infected, using different 
primary staining antibodies is shown. GFP is co-expressed on QL9 and served as a 
marker for transduction. The mean values of two separate experiments are shown.    
 
Two separate petri-dishes with HEK293T cells were either transfected or infected with 
QL9-MN and analyzed by FACS. Un-transduced cells were used for background 
subtractions in each measurement. The expression of GFP was used as a marker for 
transfected as well as infected cells. Equal amounts of cells were separately stained 
48 h after either transfection or infection, using 447-52D antibody as a positive control 
for Env expression (MFI: transfected cells 876, infected cells 39). The antibodies 5F3 
and HJ16 were tested whether they were capable to stain the same amount of cells 
(%) compared to the 447-52D positive control. Only in the case of transfected cells an 
equal result compared to the positive control was achieved for 5F3 and HJ16 
antibodies (Fig. 3.13 A). Whereas, the infected cells showed a discrepancy of 10-fold 
(5F3) and 3-fold (HJ16) reduction of the amount of positive cells compared to the 
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positive control (Fig. 3.13 B). Notably, only the signals for GFP positive cells seemed 
to correspond to similar levels (-1.4 fold, Fig. 3.13. B) of positive cells compared to 
447-52D antibody for both transfected and infected cells (Fig. 3.13 A/ B). 
Consequently, GFP was further explored to serve as a marker for Env expression as 
well.  
 
3.5.4 Correlation of GFP and envelope expression after infection 
Apart from using GFP as a marker for transduction, it was analyzed for the suitability 
as a marker for expression. HEK293T cells were infected with various amounts of 
QL9-MN and assayed for the correlation of GFP and envelope expression 48 h after 
infection. Cells were stained with 447-52D antibody, un-transduced cells were used for 
background subtraction and both GFP and 447-52D signals were analyzed by FACS 
(Fig. 3.14).  
 
Fig. 3.14 Ratio of 447-52D and GFP of infected cells 
 HEK293T cells (3 x 105) were infected with QL9-MN viruses with the volume 
indicated (MOI: 0.05 – 0.5) and stained with 50 µL 447-52D antibody (10 µg/mL) 
48 h after infection. FACS analysis is shown for the different volumes of the applied 
virus as the MFI of gated living cells. The ratio of 447-52D/GFP is shown with a 
secondary axis to indicate the connection between the expression levels of the 
envelope and GFP. The mean values of two independent experiments are shown. 
 
Even though GFP is not directly coupled with the envelope expression and especially 
not with its display, it was shown that the correlation to Env-expressing cells was more 
reliable compared to a 5F3 antibody staining (Fig. 3.13 B). Furthermore a constant 
correlation between GFP expression and the amount of envelopes displayed on the 
cells (MFI) was seen independently of the amount of infecting virus (range of MOI: 
0.05 – 0.5). The dashed line in Fig. 3.14 illustrates that the calculated ratio of GFP 
expression and displayed envelope bound by 447-52D antibody is constant. Therefore, 
GFP was further on used as both, a marker for the transduction of cells and the 
expression level of envelopes. 
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3.5.5 V3 variant affinities and optimal discrimination  
The parameters for an equilibrium binding and optimal discrimination of cells 
expressing envelope V3 variants by 447-52D antibody were determined by a time 
course and a series of antibody dilutions (Fig. 3.15). 
 
 
Fig. 3.15 Optimization of 447-52D antibody binding conditions  
 HEK293T cells were infected with an MOI of 0.3 by one of the respective QL9-V3 
variants. The cells were stained with 447-52D antibody and APC secondary antibody 
48 h after infection. All FACS analyses were gated in relation to un-infected 
HEK293T cells. The mean values of two independent experiments corrected for 
equal GFP expression are shown (see 3.5.4). A The staining with 447-52D antibody 
(10 µg/mL) was scheduled to obtain an equilibrium binding profile with 10 min 
increments. FACS analyses are shown as the MFI of every V3 construct for the 
different staining times. B The 447-52D antibody was serially diluted and incubated 
on cells for 1 h at 4°C to get a concentration-dependent binding profile. FACS 
analyses are shown as the MFI of every V3 construct stained with different 447-52D 
antibody concentrations. C Cell populations stained with 0.1 µg/mL 447-52D 
antibodies are separately shown to illustrate the differential binding at this 
concentration. D The dissociation constants Kd were determined from the 
equilibrium binding titration curves shown in (B). Data points were fitted by nonlinear 
least squares regression (One site / Fit total and nonspecific binding, Graphpad, 
Prism 5), and the resulting Kd as well as R2 values are depicted (#, non-calculable).   
 
HEK293T cells were infected separately with one of the respective QL9 based virus V3 
envelope variants. The cells were stained with 447-52D antibody in samples with equal 
amounts of cells and different incubation times (Fig. 3.15 A) or different antibody 
concentrations (Fig. 3.15 B). Longer incubation than 10 min did not lead to higher 
staining signals (MFI), thus equilibrium binding is assumed as measured by FACS. An 
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optimal antibody concentration of 0.1 µg/mL was observed (Fig. 3.15 C), which 
showed the best discrimination between the different variants. A similar general 
binding profile compared to the library binding profile described in an earlier section 
(Fig. 3.6 B) was observed. The equilibrium dissociation constant Kd, was calculated by 
fitting the data obtained by titration of 447-52D antibody using a nonlinear least 
squares regression [208,209]. The affinity of the V3 variant MN (Kd = 0.06 µM) was 
determined to have the highest affinity to 447-52D antibody, followed by HXB2 (Kd = 
0.9 µM) and CDC42 (Kd = 6.5 µM) (Fig. 3.15 D).  
To ensure optimal binding conditions in further experiments incubation times of 15 min 
and 447-52D antibody concentrations of 0.2 µg/ml, were chosen as standard 
parameters. 
  
3.5.6 Growth kinetics of bacteria transformed with V3 constructs 
The influence of a respective plasmid on bacterial growth after transformation is one 
possible issue for an unspecific bias in an enrichment procedure like panning. 
Although all V3 constructs share the same molecular background, a bias in the 
selection of variants remains possible if the bacterial growth rate is influenced by the 
differences in the V3 coding region of the plasmids. To rule this out, the growth-rate 
and accuracy of the plasmids prepared after an over-night culture were analyzed. 
Therefore the pQL9 V3 constructs were used to transform DH10B cells (2.1.5), which 
subsequently were cultivated for a DNA preparation in MTP (2.1.6). At different time 
points, the OD(600) was measured and compared for differential growth by calculating 
the individual bacterial doubling-times. The bacterial growth-rates were measured in 
five replicates. All strains consistently had a doubling-time of 78 ± 4 min. The 
subsequently, and additionally from separate overnight-cultures, isolated plasmid DNA 
were tested for correctly sized bands (data not shown) after preparation and restriction 
(1 µg each) with AleI at 37°C for 2 h on a 1 % Agarosegel (see 2.1). All samples 
consistently showed correctly sized restriction patterns, as well as equal plasmid DNA 
yields (data not shown). Thus, a bias resulting from a varying bacterial plasmid 
propagation of the different V3 variants was excluded. 
 
3.5.7 Realtime PCR analyzes 
Evaluating the status of enrichment on the basis of sequencing randomly chosen 
samples of single bacterial clones is dependent and therefore limited by the sample 
size. A practically sample size for manual processing was considered to be one MTP 
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(94 single clones) per round of enrichment. These generated values were accurate 
related to the parent population with ± 10 %, within a confidence level of 95% 
[210,211]. A Realtime PCR reaction was established to increase the statistical 
accuracy by analyzing the relative portion of any out of five V3 envelope variants in a 
plasmid DNA sample of usually 0.05 ng DNA (≈ 4 x 106 plasmids) after every round of 
enrichment. Within a confidence level of 95%, the generated values were accurate 
related to the parent population with ± 0.05 %.  Thus, a higher accuracy in the readout 
of the enrichment status was possible. Besides, providing a tool for the confirmation of 
the enrichment status, determined by sequencing. However, a Realtime-PCR-based 
method is only practicable for the limited number of variants used within the V3 library 
and not for any proposed larger libraries. A critical parameter for PCR based 
experiments is the efficiency with which a primer pair is able to amplify a DNA 
sequence [212]. Therefore, efficiency values of primer pairs (reference and specific 
primers) designed for analytical purposes as well as for primer pairs used to amplify 
the complete envelope genes within the panning procedure (8H1/H2) were determined 
(Fig. 3.16 A/B). Different PCR efficiencies would result in a biased PCR amplification in 
favor of one of the V3 constructs. The calculated efficiency values were taken into 
account for the calculations of relative amounts of V3 variants probed in section 3.6. 
The amplification of the complete V3 envelope by PCR was un-biased according to the 
8H1/H2 primer pair, which performed with similar efficiencies on all tested V3 envelope 
variants within the given margin of error (Fig. 3.16 B).  
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Fig. 3.16 Efficiency and verification of the specificity of Realtime PCR analyses   
 A Schematic overview of the Realtime PCR components. Consensus sequences are 
color-coded. Sequences corresponding to the envelope are black and to the QL9 
plasmid are grey. Oligonucleotides like primers or probes are grey, black or colored 
arrows. The colors and orientation visually connect the plasmid sequence to its 
oligonucleotide binding area. The Probe is 5’ labeled with FAM and 3’ quenched by 
BHQ1. B PCR efficiencies for all primer pairs used on the V3 plasmids were 
calculated to demonstrate comparable efficiencies between the different V3 
constructs. Efficiencies for primer 8H1 and 8H2 were tested with SYBR Green 
(mean and SD of two separate experiments). The other primers were tested with 
probe based Realtime PCR. C Probe based Realtime PCR amplifications on 
plasmid mixtures were done to verify the specificity of every possible combination of 
the V3 variants used. The name of the colored samples indicates whether the tested 
V3 variant is present or absent. Technically, triplicates of 5 µL of every sample 
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mixture (1 ng/µL) were tested with its corresponding specific Primer-r, but with equal 
Primer-f and Probe. Rn values (normalized Reporter) are the ratio of the 
fluorescence emission intensity of the reporter (Probe) to the fluorescence emission 
intensity of the passive reference dye (i.e. ROX). Rn is plotted against the PCR 
cycle number to illustrate the amplification of PCR products. 
 
 
Realtime PCRs using plasmid mixtures of QL9 V3 envelope variants confirmed the 
specificity of the primer pairs designed for analytical experiments (Fig. 3.16 C). Each 
primer pair was probed using a mixture of plasmid with (positive) and without 
(negative) the appropriate V3 envelope. All tested primer pairs specifically interacted 
only with the V3 envelope variant for which they were designed. 
 
3.5.8 Summary 
A new lentiviral vector (QL9) was designed and characterized. With the integration of 
GFP into QL9, a marker for transduction and equal envelope expression was 
introduced. Optimal parameters for the discrimination of QL9 infected V3 envelope-
expressing cells were determined. Realtime PCR was introduced in addition to 
sequence analyzes of single bacterial clones, as a statistically more reliant analytical 
tool to analyze the amount of distinct V3 variants in a mixture of plasmids. A bias in the 
enrichment of V3 variants with the benefit to one of the constructs was excluded 
concerning differing bacterial growth as well as differing PCR efficiencies primer pairs 
used. 
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3.6 Lenti-cellular display and FACS-mediated panning  
3.6.1 Lenti-cellular display and panning procedure (FACS-panning) 
A lenti-cellular display and FACS-panning procedure was designed considering the 
experiences of earlier developed panning procedures (see 3.2 / 3.4) and addition of 
new techniques addressing the discovered weaknesses. With the development of 
pQL9, a reliable determination of low MOI infection and normalization of envelope 
expression of cells is possible. Furthermore the CcdB-mediated QL cloning strategy 
enabled a convenient, standardized and efficient process for the cloning of envelope 
genes. Utilizing Realtime PCR a second tool besides sequencing of single bacterial 
clones is available to specifically determine the amount of each V3 variant within a 
mixture of DNA (3.5). Although this PCR-based assay is only practicable for the 
development stage using limited numbers of V3 variants, the increased accuracy and 
validation of the obtained results by a separate analysis tool, is of advantage. Further 
on, the previous MACS-mediated enrichment process was substituted with a single 
cell FACS sorting procedure. This essential modification enabled the selection of cells 
based on their individual properties. Hence, unwanted avidity effects were avoided by 
(I) gating for cells that display Env in equal amounts, and (II) the separation of cells 
displaying Env that bind with the desired higher affinity towards the applied 447-52D 
antibody (Fig. 3.17).  
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Fig. 3.17 Schematic overview of the FACS-panning procedure 
 HEK293T cells are transfected with lentiviral-vector-based constructs (QL9 + pTN 
pack, pVSV-G) (left). The produced virus is pseudotyped with VSV-G and displays 
envelopes coded on QL9. The linkage between its genotype and phenotype is not 
given (“unlinked” virus library). By low MOI infection of new cells, a linkage between 
genotype and phenotype is achieved for the infected cells (top). Broadly neutralizing 
antibodies (bNab) are applied to bind to these cells, expressing envelopes of interest 
(upper right). The envelopes with the highest affinity to the bNab are selected by a 
FACS-sorting procedure (lower right). The selected cells are collected and lysed, 
before amplifying the envelope genes. Amplification is done from genomic DNA 
(Nested PCR). The recovered envelope genes are cloned into QL9 plasmid and 
analyzed by sequencing and Realtime-PCR (RT-PCR) (bottom left). Fresh cells are 
transfected (together with pTN pack and pVSV-G) to produce new virus for Low MOI 
infection of fresh cells, thus entering a new round of selection.  
 
The FACS-panning procedure starts with the production of viruses by a triple-
transfection of pQL9-V3-library, packaging-, and VSV-G- plasmid (see 2.3.3). Any 
transfected cell receives multiple library variants at once. Therefore, arising viruses 
displays diverse Env variants that not stringently coincide with the Env gene encoded 
on their genome (unlinked virus library). A linkage between genotype and phenotype is 
reached by a low MOI (0.1) infection (see 5.3). Consequently, infected cells receive 
only one viral genome and express only one V3 Env variant. Thus, low MOI infected 
cells are called “linked cells”. The broadly neutralizing antibody (bNAb) 447-52D is 
applied to the envelope expressing cells to bind towards the envelopes anchored on 
the plasma membrane surface. The marker GFP is used to gate for equally Env 
expressing cells (see 3.5.4). A FACS sorting procedure selects cells expressing 
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envelopes with high affinity towards the bNAb applied (see 3.6.2). The sorted cells are 
lysed and the envelope genes are amplified from genomic DNA (Nested-PCR; 2.1.1). 
The recovered envelope genes are cloned (2.1.4) into pQL9, and bacteria are 
transformed. Single bacterial clones are analyzed by sequencing, and plasmid DNA is 
analyzed by Realtime PCR (RT-PCR; 2.1.2). The obtained plasmids are used to 
produce a new batch of VSV-G pseudotyped viruses and to begin another round of 
panning. 
 
3.6.2 FACS sorting strategy 
A series of different gating strategies was tested using pQL9 based V3 library 
transfections and infections of cells, in order to evaluate parameters for an optimal 
discrimination of envelope V3 variants (data not shown). Gating for living, single cells 
and choosing populations with an even GFP expression yielded the best results. 
Therefore, a VSV-G pseudotyped batch of virus was produced by triple transfection 
(see 2.3.3) of HEK293T cells using a QL9 plasmid (-mixture, see 3.6.3), packaging- 
and VSV-G- plasmids. Subsequently, fresh HEK293T cells were infected with low MOI 
(0.1) as measured by counting GFP expressing cells. Subsequently a FACS-panning 
(3.6.1) was performed using ∼ 4 x 107 cells. One typical sorting experiment is shown to 
illustrate the FACS sorting strategy. Therefore, 50,000 events were recorded and a 
series of hierarchical gates were applied to isolate single, high affinity, Env displaying 
cells (Fig. 3.18 A-B).  !
Results 
- 66 - 
 !
Fig. 3.18 FACS-sorting strategy  
 A The living population of infected cells (see main text) was gated according to their 
size (FSC-A) and granularity (SSC-A) (left). Further gates were applied to eliminate 
doublets by adjusting the parameters of FSC (middle) and SSC (right) according to 
height and width. B GFP positive cells were gated within their main population to 
avoid highest (possibly multiply infected) and lowest (possibly background noise) 
GFP expressing cells (left). Sorting population is gated for highest APC (447-52D 
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antibody) signals in relation to GFP signals. Therefore a triangle shaped Gate (Gate 
6) was chosen. Cells which appear in the upper left corner are supposed to have the 
highest APC to GFP ratio and may therefore display an envelope with high affinity to 
the tested antibody (447-52D) (middle). The complete Gate hierarchy starting from all 
events, to the events sorted (Gate 6) is shown (right). C Evaluation of the triangle 
gate strategy: HEK293T cells (13 x 106) were infected with low MOI (0.1) by each 
QL9-V3 variant, respectively. The cells were stained with 447-52D antibody and APC 
secondary antibody 48 h after infection. Cells were analyzed by FACS according to 
the gating strategy described in part A and B. Cells that appeared in Gate 5 are 
shown in a linear dot plot and were further analyzed by calculating a linear 
regression curve (purple). Representative variants MN, HXB2, and SF33 illustrate 
that with increasing affinities cells shift to the upper left direction of the gate as 
demonstrated by an increasing slope value. The triangle shaped Gate 6 is shown in 
a log-scale dot plot. The numbers of events counted for Gate 5 and Gate 6 are 
shown below each plot, respectively. Consequently, decreasing amounts of cells 
equals decreasing affinities of Env, as detected in the sorting Gate 6, ranging from 
10 counts of MN, 2 of HXB2 and 0 of SF33.   
 
 
The applied gating strategy selects for (I) the living fraction of cells according to their 
size, as measured by the forward (FSC) and side (SSC) scatter area (A). (II) Since 
cells tend to rotate while measuring the height (H) and width (W) parameters for both, 
FSC and SSC were adjusted to select for the lower, main population, to discriminate 
single cells (Fig. 3.18 A). (III) In order to decrease the chance for selecting multiply 
infected cells, as well as to avoid background noise, the highest and lowest GFP 
expressing cells were excluded in choosing the main population of GFP positive cells 
(Gate 5, Fig. 3.18 B).      
A triangle shape was chosen for the FACS-sorting gate (Fig. 3.18 B, Gate 6) to select 
cells with the highest ratio of 447-52D binding related to envelope expression 
(represented by GFP). Thus, it is assured that primarily envelope variants with high 
affinity towards 447-52D antibody and not with unusually high expression are selected. 
 
A separate experiment was performed to evaluate the proposed triangle gating 
strategy for high affinity Env selection. Therefore 13 x 106 HEK293T cells were 
infected with low MOI (0.1) by each QL9-V3 variant, respectively. The FACS-sorting 
strategy was performed individually for each variant as described above. The cells 
were probed for high affinity towards 447-52D antibody by calculating a linear 
regression curve for cells that appeared in Gate 5. Representative variants of the 
model V3 library are shown (Fig. 3.18 C). The distinct slopes of the regression curves 
illustrate the varying ratio of 447-52D / GFP for each Env variant, respectively. A 
higher ratio equals a higher affinity of 447-52D towards the respective Env [138]. A 
high stringency for selecting only high affinity Envs was proposed by gating only for the 
top < 10 events out of 50.000 counts, using the triangle shaped selection Gate 6 (Fig. 
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3.18 B, C) [138,209]. According to the evaluation experiments a distinct difference in 
cell counts for MN (10), HXB2 (2) and SF33 (0) suggested a stringent discrimination 
between the V3 variants. As this encouraging evaluation was done with separate 
infected cells, a proof-of-concept experiment using a mixture of MN and SF33 
followed.  
 
3.6.3 FACS-panning using one binding and one non-binding V3 variant 
A proof-of-concept for the FACS-panning procedure of envelopes binding towards 
447-52D antibody was done with mixtures of QL9-MN (binding) or QL9-SF33 (non 
binding) V3 envelope variants. VSV-G pseudotyped virus batches were produced by 
triple transfection (see 2.3.3) of HEK293T cells with three different QL9-MN and QL9-
SF33 plasmid ratios (MN / SF33: (I) 5 % / 95 %, (II) 25 % / 75 %, (III) 50 % / 50 %), 
each with packaging-, and VSV-G- plasmids. Subsequently, fresh HEK293T cells were 
infected with low MOI (0.1) and FACS-panning (3.6.1) was performed using ∼ 4 x 107 
cells for each of the three samples. The envelope genes of sorted cells (∼ 1000 cells 
per sample) were recovered and cloned into pQL9 plasmids. The distribution of V3 
variants during two rounds of selection were monitored by sequencing plasmids from 
single bacterial clones (one MTP) and performing Realtime PCR (RT-PCR) with 
plasmid preparations. The V3 envelope distributions were analyzed with samples 
directly before FACS-sorting (Input) and after the enrichment rounds (1st, 2nd). The 
amount of each V3 variant is shown as the count of identified single bacterial clones 
out of sequencing 94 clones (one MTP) and additionally by calculating the relative 
amount of every V3 variant in the respective plasmid preparations by RT-PCR (Fig. 
3.19 – 22 A). RT-PCR reactions with primer pairs specific for each V3 variant (3.5.7) 
were performed in triplicates and the mean Ct  (crossing point, also known as CP) 
values were determined by the usage of the StepOne software (Life technologies 
corporation). The portions of V3 envelope variants (%) in a mixture of plasmids were 
determined by calculating relative amounts. Individual amounts of plasmids were 
calculated by the formula E-Ct (E = Efficiency of PCR) for each V3 specific PCR. 
Subsequently, the portion of each V3 variant in a mixture was calculated in relation to 
the sum of all variants detected [213-215]. The total amounts of plasmids in each 
sample were calculated using a reference primer pair (3.5.7) that independently of the 
respective V3 variant amplifies a region on the plasmids used. To depict conformity of 
the used relative quantification method the relation of the calculated reference values 
to the sum of the V3 variants values are shown (%) (Fig. 3.19 – 22 B).   
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Fig. 3.19 FACS-panning-mediated enrichment of V3 envelope variants displayed on 
HEK293T cells  
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Fig. 3.19 FACS-panning-mediated enrichment of V3 envelope variants displayed on 
HEK293T cells 
 A pQL9 plasmid mixture of envelope V3 variants containing 5% MN and 95% SF33 
was prepared. HEK293T cells (13 x 106) were transfected (pQL9-mixture, pTN pack, 
pVSV-G) to form an un-linked virus library. Fresh HEK293T cells (13 x 106) were 
infected with low MOI (0.1). The infected “linked” cells were applied to a FACS-
sorting procedure 48 h after infection. The envelope genes were amplified from the 
genomic DNA of the collected cells, cloned into pQL9 and analyzed by sequencing 
and Real-time-PCR. Fresh cells were transfected with the new pQL9 mixture 
(together with pTN pack and pVSV-G) to produce new virus for Low MOI infection of 
fresh cells and to enter another round of selection. The mean values of two 
independent experiments are shown. A The relative counts (upper panels) or 
amount (lower panel) per variant of the input mixture, 1st and 2nd round are shown 
for analyzes by sequencing (one MTP) and RT-PCR (Efficiency-Ct as % of each 
variant) respectively. B For every RT-PCR sample the total amount of pQL9 
plasmids was probed. A reference primer pair was used that amplifies a sequence 
independent of the envelope gene inserted into pQL9.  !! !
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Fig. 3.20 FACS-panning-mediated enrichment of V3 envelope variants displayed on 
HEK293T cells 
 A pQL9 plasmid mixture of envelope V3 variants containing 25% MN and 75% SF33 
was prepared. The Panning procedure was performed and results were calculated as 
described in Fig. 3.19. A The relative counts or amount per variant of the input 
mixture, 1st and 2nd round are shown. B Total amount of pQL9 plasmids. 
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Fig. 3.21 FACS-panning-mediated enrichment of V3 envelope variants displayed on 
HEK293T cells 
 A pQL9 plasmid mixture of envelope V3 variants containing 50% MN and 50% SF33 
was prepared.  The Panning procedure was performed and results were calculated as 
described in Fig. 3.19. Statistics are calculated using the unpaired t-test or 1way-
ANOVA followed by "Tukey's Multiple Comparison” test if groups were compared      
(* P<0.05; ** P<0.01; *** P<0.001). A The relative counts or amount per variant of the 
input mixture, 1st and 2nd round are shown. B Total amount of pQL9 plasmids. 
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The enrichment of the MN variant out of differently proportioned mixtures starting with 
5% MN (Fig. 3.19), 25% MN (Fig. 3.20) and 50% MN (Fig. 3.21) could be 
demonstrated. Significant (*) differences were calculated either by an unpaired t-test if 
two columns in one group were compared or using the 1way-ANOVA test followed by 
"Tukey's Multiple Comparison Test" if columns between all groups were compared  
(* P<0.05; ** P<0.01; *** P<0.001). The mean values of two independent experiments 
are shown. 
Within the panning targeted for an input value of 5% MN, at least a doubling of the 
amount of MN within 2 rounds was achieved. Both analysis methods showed a 
consistent increase of MN throughout the panning rounds as analyzed by sequencing 
(2%, 6%, 10%) and RT-PCR (5%, 7%, 12%). However, concerning both methods, no 
statistically significant enrichment was achieved, thus only a trend towards higher 
relative amounts of MN could be observed (Fig. 3.19 A). The trend for a higher 
deviation of the total plasmid amounts calculated relative to the sum of both 
individually detected plasmids throughout the panning rounds was noted (Fig. 3.19 B). 
This implies an increasing discrepancy to the V3 specific measurements and may 
explain the increasing standard deviation of the measured V3 values appearing in the 
second round. 
During the panning starting with 25% MN, at least a doubling of the amount of MN 
within 2 rounds was achieved again. Both analysis methods showed a consistent 
increase of MN throughout the panning rounds as analyzed by sequencing (20%, 26%, 
44%) and RT-PCR (22%, 34%, 44%). Again only an enrichment trend of the V3 variant 
MN is observable still lacking statistical significance, when comparing Input to first and 
second round (Fig. 3.20 A). The total amount of plasmid was calculated relative to the 
sum of both specifically detected plasmids and consistently resulted in values of 
∼100% throughout the panning rounds (Fig. 3.20 B).  
Within the panning starting with 50% MN, a statistically significant enrichment of the 
V3 variant MN was observed as indicated. A consistent increase of MN throughout the 
rounds of panning, as analyzed by sequencing (55%, 69%, 86%) and RT-PCR (50%, 
70%, 91%) was demonstrated. The trend of a doubling rate of MN within 2 rounds of 
panning was almost achieved again. A statistically significant enrichment of MN was 
obtained, when comparing Input to the second panning round as calculated for both 
analysis methods. Additionally, a statistically significant enrichment of MN was 
observed comparing first to second round, but remained restricted to the calculations 
of the sequencing method (Fig. 3.21 A). Moreover, the total amount of plasmids 
detected, consistently corresponded to the amounts detected by the specific V3 
related primers (Fig. 3.21 B). This “proof-of-concept” study demonstrates the ability to 
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enrich a binding envelope at the cost of a non-binding envelope, by applying the 
FACS-based panning procedure.  
 
3.6.4 FACS-panning using the complete V3-library 
The complete V3 envelope library was screened with the FACS-panning procedure. A 
VSV-G pseudotyped batch of virus was produced by triple transfection (see 2.3.3) of 
HEK293T cells with a QL9 plasmid mixture (20% of each V3 variant), packaging- and 
VSV-G- plasmids. Subsequently, fresh HEK293T cells were infected with low MOI 
(0.1) and a FACS-panning (3.6.1) was performed using ∼ 4 x 107 cells. The envelope 
genes of sorted cells (1300 ± 600 cells each round) were recovered and cloned into 
pQL9 plasmids. The distribution of the different V3 variants throughout the selection 
rounds are calculated and illustrated similar to the descriptions in section 3.6.3. The 
enrichment of the variant MN out of an equally proportioned mixture was proven. 
Significant (*) differences of V3 envelope amounts were calculated by the 1way-
ANOVA test followed by "Dunnett's Multiple Comparison" test (* P<0.05; ** P<0.01; 
*** P<0.001). The mean values of four independent experiments are shown (Fig. 3.22).  
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Analysis by sequencing     
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Fig. 3.22 FACS-sorting-mediated enrichment of V3 envelope variants displayed on 
HEK293T cells 
 A pQL9 plasmid mixture of envelope V3 variants containing equal amounts of MN, 
RF, CDC42, HXB2, and SF33 was prepared. The Panning procedure experiments 
were done similar to Fig. 3.19. Statistics are calculated using the one way ANOVA 
test and “Dunnett’s” post test (n.s. P>0.05; * P<0.05; ** P<0.01; *** P<0.001). A The 
relative counts or amount per variant of the input mixture, 1st and 2nd round are 
shown. B Total amount of pQL9 plasmids. 
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The panning described above, aimed at an Input value of 20% for each Env variant. 
Roughly, a similar Input distribution of Env was achieved (Fig. 3.22 A, Input). Both 
analysis methods showed a consistent increase of MN throughout the rounds of 
panning as analyzed by sequencing (30%, 38%, 67%) and RT-PCR (19%, 31%, 58%). 
Thus, at least doubling the amount of MN within 2 rounds was achieved, consistently 
to the preliminary experiments shown in section 3.6.3. Comparing the rounds of 
panning as separate groups, MN was significantly enriched, as indicated for both 
analysis methods. Additionally, regarding the second round of selection, a significant 
enrichment of MN in relation to all other V3 variants was observed as indicated (Fig. 
3.22 A). The total amount of plasmids (reference primer pair) was calculated relative to 
the sum of the individually detected V3 plasmids (specific primer pairs) throughout the 
rounds of panning. In every panning round nearby ∼100% plasmid total amounts were 
measured, thus a consistent detection of all individual plasmids was proven (Fig. 3.22 
B). With this extended “proof-of-concept” study the ability to enrich a binding envelope 
not only in presence of one non-binding envelope (3.6.3), but also in presence of 
various envelopes with distinct binding capabilities (3.5.5) was demonstrated. Taken 
together, the applied panning procedure resulted in enrichment rates of ∼ 3-10 fold 
after 2 rounds of selection (Table 3.4).  
 
Table 3.4  Enrichment of Env variant MNa 
 The specific enrichment of the V3 variant MN is calculated for each FACS-panning.  
Panning  Ratioa of 
Env recovered after 2 rounds (%) / Env Input (%) 
 Fold enrichmentb 
  MN Non-MN   
5%   MN      (Fig. 3.19)  2.68 0.92  2.91 
25% MN      (Fig. 3.20)  1.97 0.72  2.71 
50% MN      (Fig. 3.21)  1.8 0.18  9.88 
      
Library Screen (Fig. 3.22)  3.09 0.51  6.01 
 
a Only values obtained by Realtime PCR were considered 
b Calculations were made according to the formula  !"#$%&! "!#!!!"#$%&! "!#!!!! !!"#$%&! "#!!"!#!!"#$%&! "#!!"!#!  [149] 
# round of panning 
 
The amounts of Env recovered after 2 rounds of selection in relation to Input amounts 
were summarized. An enrichment of ∼3-fold was calculated for the panning procedures 
starting with 5% MN or 25% MN, and ∼10-fold for the panning starting with 50% Input 
amounts of MN. The enrichment rate of MN as calculated for the model library screen 
is ∼6-fold. Thus, the capability of the developed panning procedure to enrich the 
highest affinity Env variant was demonstrated, even in the presence of several 
competitive Envs such as the HXB2 variant.   
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3.6.5 Summary 
A lenti-cellular display and FACS-panning procedure was designed and evaluated. A 
FACS sorting strategy was established by gating for single cells with average GFP 
expression (= envelope expression) and sorting by a triangle shaped gate for cells with 
a high 447-52D / GFP signal, allowing the sorting of high affinity Env variants. With 
proof-of-concept studies comprising different proportions of either binding- and non-
binding V3 envelope variants, or the use of a panel of five V3 envelope variants with 
different affinities, the enrichment of a V3 variant (MN) with highest binding affinity 
towards 447-52D bNAb was demonstrated. Statistical tests approved that after two 
rounds of selection with the V3 library, a significant enrichment of the V3 variant MN 
was achieved (P<0.05).  
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4. Discussion 
4.1 Development of a display and panning platform 
It was shown that vaccination trials using monomeric Env [216] were inferior in eliciting 
presumptive correlates of protection [94] such as bNAbs or cellular immunity. 
Requirements of a proposed protective vaccine comprise both almost sterilizing 
antibody-mediated immunity, and rapid CTL-mediated elimination of infected cells 
[217]. Since bNAbs were discovered, the properties of their exact target sites have 
been subject to ongoing examination, and been used as a guideline for vaccine design 
efforts (reverse vaccinology) [108,120-125]. Therefore, optimally representing 
immunogenic bNAb epitopes, excluding non-neutralizing epitopes, and displaying 
distinct native states of Env, including quaternary epitopes, represent some of the 
desired properties of an ideal trimeric immunogen [218]. 
In this thesis, techniques were developed to identify HIV-1 envelope variants intended 
to be displayed in trimeric, membrane-bound states that bind with high affinity towards 
a given bNAb (e.g. 447-52D). The resulting “lenti-cellular display” and FACS-mediated 
panning procedures enable the selection of Env in a mammalian context, intended to 
display Env natively, and providing access to quaternary structures [219]. Existing, 
well-established display and selection techniques such as phage display [130], 
retroviral display [149] and others [144] were considered, and the overriding strategy 
was adapted to be consistent with the proposed requirements of a trimeric, membrane-
bound state of Env.  
  
4.1.1 Viral display and panning (AIO-platform) 
The already described [149] avian leukemia virus (ALV) display is based on chimeric 
envelope proteins. In the proposed HIV-1 library, Env variants are intended to be 
displayed in a mostly native state to ensure proper access to bNAb binding sites. 
Therefore, the obvious method of choice to display such Env variants, considering the 
criteria above, was using the HIV-1 virus itself. In close analogy to the ALV display 
method [149] (see 1.6), a technique was designed based on HIV-1 (AIO; see 3.2.1). 
The NL4-3 derived proviral vector pTN7stop was chosen as a basis for developing 
pTN-AIO, since it was already proven to form replication competent, but Env negative 
virions. Furthermore, it expresses an integrated reporter protein (R.Luciferase), which 
was considered a suitable integration site for a prospective Env library. Therefore, two 
further modifications were made: (I) enhancing the expression level at the reporter site 
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by integrating a Kozak consensus sequence upstream of the reporter protein; and (II) 
integrating another reporter protein (HSA) into the ORF of vpr, which becomes 
incorporated into the cellular membrane [186,187]. Thus, infected cells were easily 
detected by anti-HSA antibody staining (Fig 3.4 A).  
Besides the detection of infected cells, HSA should enable potential virion and cell 
precipitation or enrichment assays. Despite initial successful steps in developing the 
AIO platform, in terms of detection and replication of AIO-HSA (see 3.2.1-3), only 
unsatisfactory amounts of virus bound to immobilized antibody were recoverable (∼1-
2 %, 5-10 x 103 particles). Therefore, any proposed Env library would be limited to the 
number of virions that can be bound. The variability of a prospective library of Env 
variants would have to be limited in order to ensure proper representation of each 
variant. Usually over-representation of approximately 20-fold is estimated to reach 
95% statistical confidence of screening every variant at least once [220]. Hence, the 
efficacy of a library screening method strongly depends on being able to represent the 
variability of a library several-fold [221,222].  
Despite testing several conditions, only low amounts of virions were regularly 
captured. Since the produced batches of virions were found to be infectious, and 
therefore stable over a usual range (5 x 103 TU/ng p24) [190], a loss of stability is 
thought to occur during the panning procedure. Several incubation and washing steps 
are applied during panning and may lead to unspecific disruption of virions applied. 
Despite these problems, increasing stringency of washing conditions is required to 
efficiently enrich the strongest binders [223]. Enhancing the amount of bound HIV-1 
virions was not possible, and simply scaling up the amounts used is uneconomical, as 
well as technically limited.  
As an alternative to using virions, cellular display was considered as the basis for 
developing an Env display system. HEK293T cells, which were formerly used to 
produce HIV-1 viruses, were considered to meet the proposed requirements for Env 
display, especially since these cells have been used for cellular display purposes 
[138,139]. Thus, the AIO-platform was abandoned in favor of a cellular display 
technique. To enable thorough testing of the conditions needed for successful 
screening, a model Env library and corresponding bNAb partner were selected. 
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4.1.2 An HIV-1 envelope V3 library to adjust panning parameters  
The well-characterized bNAb 447-52D [113,117,191] was chosen, since former 
experiments of Gorny et al. [117] using V3 peptides from different HIV-1 strains, 
resulted in distinct binding patterns with different Kd values. It was therefore likely that 
different V3-bearing Env variants would be bound by 447-52D antibody in a manner 
that allows discrimination by affinity. The complete V3 region of a 96ZM651-derived 
gp145 Env (see 3.3) was exchanged by the V3 regions of the mentioned isolates with 
different Kd values towards 447-52D. After transient expression in 293T cells, binding 
by 447-52D antibody was tested. Interestingly, the cellular-based membrane-bound 
Env binding pattern (for variants RF, CDC42, HXB2; Fig. 3.6) differed from the 
reported peptide-based binding pattern, with the exception of the best binding (MN) 
and non-binding (SF33) V3 variants.  
Considering that a peptide-based assay differs greatly from a cellular-based assay, the 
observed discrepancy is not unexpected. Since there are many putative structural or 
steric differences in accessing epitopes on peptides compared to membrane-bound 
Env, neither a reproduction, nor the exact binding profile was anticipated, or needed. 
Furthermore, different readout strategies were used to determine a binding pattern. 
The peptide-based assay used a modified ELISA technique [117,224] to calculate 
specific Kd values, whereas the cellular-based FACS assay compared MFI values. 
However, the 447-52D antibody binding pattern obtained for cellular-based, 
membrane-bound Env was considered a feasible challenge for a panning procedure 
aiming to enrich the best 447-52D antibody binding Env variants.  
  
          
4.1.3 Cellular display and MACS-mediated panning 
Since Env is expressed and integrated into the cellular membrane prior to the budding 
of virions (see 1.2), cellular display probably also closely mimics the properties of a 
membrane-bound, trimeric Env. Although viral-based display theoretically has the 
advantage of representing greater variabilities in small volumes (∼107 TU/mL), this was 
confounded by the massive loss (98-99%, see 3.2.4) of particles during the panning 
process. Cellular display, in comparison, is rather more restricted in terms of 
propagating practicable clone numbers (e.g. 104 - 106 infected cells, see 3.4.3, 3.6), 
but has superior performance in terms of sufficient recovery and reliable analysis after 
the enrichment steps (see 3.4.2). Since the MACS system is a widely used application 
for enriching fragile and rare cells [225,226] the recovery rates for positive cells were 
adequate (Fig. 3.8). Although initial separation experiments (Fig. 3.9. A) showed 
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successful enrichment of binders according to the previously determined binding 
pattern, this was only true in the case of separately transfected cell mixtures. In other 
words, MACS panning succeeded if cells were transfected separately, each with one 
of the V3 variants of the model library, and subsequently mixed in a 1:1 ratio, but failed 
if cells were transduced with a mixture of V3 variants. Even an attempt to mimic 
conditions of separately transfected cells by using low MOI infections (according to 
5F3 staining, see 3.4.3), ensuring phenotype and genotype linkage, failed with non-
specific enrichments (see Fig. 3.10).  
To explain these findings, potential drawbacks were hypothesized: (I) If cells express 
and display Env in different amounts, MACS may mediate selection in favor of a higher 
level of expression (avidity), instead of the intended higher affinity of Env. (II) An 
underestimation of the 5F3 antibody determined low MOI would have resulted in an 
unlinked-library display, and consequently similar failure in selecting the strong binder, 
as has been documented. However, neither hypothesis was assessable within the 
MACS system, which is rather like a “black-box” in terms of having no option to adjust 
selection parameters, such as distinct expression levels of Env during the selection 
process. Furthermore, the viral vector used so far, lacks a separate marker gene. 
Thus, MOI and display of Env on cells were determined jointly by staining Env on 
infected cells using the antibody 5F3 in a FACS based readout in separate samples. 
Therefore, the precision of determining low MOI depended on the accuracy of 5F3 
antibody staining all infected cells (% pos. cells). If cells were infected and expressed 
Env that is disrupted in terms of 5F3 antibody binding, the determined MOI would be 
biased. To disconnect determining the MOI from the antibody 5F3, new viral vectors 
(Table 3.3) were developed, bearing a separate marker gene (GFP) to instantly 
determine the MOI after infection of cells. 
 
    
4.1.4 QL viral vector development  
During the design of viral vectors, a more convenient strategy for the cloning of Env 
library genes was introduced. The “QL” (Quick-Ligation) procedure involves using the 
Esp3I restriction enzyme (Typ IIS) and CcdB [168] selection marker (see Fig. 3.11). A 
conceptually similar technique was recently applied for a cloning vector called 
pINITIAL by Geertsma et al. [167]. Correspondingly, using a Typ-IIS restriction enzyme 
together with standard T4 ligase enabled a one-step restriction and directed-ligation 
reaction. Moreover, with QL-mediated cloning the CcdB marker gene, which is toxic for 
the DH10B E.coli strain used, ensured reliable growth only if Env successfully 
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substituted CcdB. Taken together, the QL procedure simplified (one-step) and 
therefore improved the ligation and cloning process of Env genes (see Fig. 3.11). 
Another desired feature was using a marker (GFP) for infection that is directly encoded 
on the viral vector and easy to detect. Thus, the MOI can be determined independently 
of an indicator cell line or staining with an antibody. 
It required several approaches (see 3.5.2) to successfully implement GFP as a 
separate marker gene into the viral vector that reliably indicates a transformed cell. 
Two criteria had to be met: First, expression of GFP had to be independent of the 
cloned Env gene (Fig. 3.12 A). Second, expression of both the Env V3 variant MN 
bound by 447-52D antibody and a similar signal of GFP corresponding to the amount 
of positive cells (%) was desired (Fig. 3.12 B). Interestingly, only the pQL variants that 
encoded the GFP marker upstream of Env (pQL9 and 11) successfully passed the 
selection criteria. All other variants were either almost undetectable, or positive only for 
GFP or Env, or GFP expression decreased drastically once Env was expressed from 
the same vector. Those effects were not the subject of further experiments, but might 
be due to promoter interference as demonstrated by Curtin et al. [227], when 
heterologous promoters were used (pQL2, -3, -4, see Table 3.3). Although Curtin et al. 
particularly chose the widely used promoters CMV in combination with EF1α, they 
hypothesized that interference between heterologous promoters occurs relatively 
often.  
Consequently, an IRES site was explored in subsequent pQL vectors (pQL5 – 10, see 
Table 3.3). Since lower IRES-dependent second gene expression is known in many 
cases [228], various pQL designs were made in order to express Env as the first gene 
and the known strong fluorescent GFP as the second gene. Interestingly, when Env 
was successfully expressed, these vectors (pQL5, 7, 8, 10; see Fig. 3.12) mediated a 
consistently strong reduction in detectable GFP positive cell numbers, instead of the 
proposed tolerable decrease in GFP (second gene) expression strength.  
Eventually, the switch of gene positioning accomplished in the vector pQL9 resulted in 
homogenous expression of both GFP (first gene) and Env (second gene). The 
particular effect was not the subject of further experiments, but is consistent with prior 
studies, which have shown that the expression of the gene downstream of IRES 
inconsistently depends on the first gene sequence upstream of IRES [229,230]. Thus, 
GFP was successfully expressed if positioned as the first gene and a model Env 
library with differing sequences as the second genes (see Fig 3.12 C/D). Besides, the 
varying, unpredictable influence on the second gene expression mediated by different 
gene sequences located at the first position was excluded, since GFP would be 
constantly used at this critical first position.  
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Another homologous GFP and Env expressing vector was developed, pQL11, by 
introducing the TaV (Thosea asigna virus) p2A peptide. Where p2A sequences occur 
within an ORF, the formation of the peptide bond at the C-terminus of (each) 2A does 
not occur. Thus each protein is stoichiometrically produced as a discrete translational 
product [206]. For this widely used type of peptide sequence [206,231] it was shown 
that genes containing an N-terminal signal sequence can inhibit the functionality of 
p2A sequences, if positioned as the first gene [232]. Thus, Env was again positioned 
as the second gene to avoid any possible interference (see Table 3.3).  
Since pQL9 was constructed earlier than pQL11, it was chosen as the standard viral 
vector in the following experiments. After the V3 Env library had been cloned into QL9, 
determining the MOI using GFP and 5F3 antibody was compared following 
transfection or infection. The ratio of positively stained cells using 5F3 antibody versus 
GFP should ideally be 1:1, due to a QL9-carrying cell (GFP+) expressing GFP as well 
as Env. This was nearly achieved after transfection (Fig. 3.12 C), but not after infection 
(Fig. 3.12 D) with any of the QL9 variants.  
In fact, this was the first strong evidence supporting the proposed underestimation of 
low MOIs determined (see 3.4.4 / 4.1.3) by the antibody 5F3 in earlier experiments 
(see 3.4). For clarification, a separate experiment was performed using cells either 
transfected or infected with the QL9-MN variant. Both batches of cells were analyzed 
for the expression of GFP as well as staining of Env using 447-52D (positive control), 
5F3 and HJ16 antibodies. No differences in cells assessed as positive were observed 
for cells that had been transfected (Fig. 3.13 A). However, in the case of infected cells, 
it was confirmed that using the 5F3 antibody had led to an up to 10-fold gap between 
the accuracy in determining the number of positive cells (%) compared to the 447-52D 
antibody (Fig. 3.13 B). This means a desired low MOI of 0.1 calculated using data 
obtained from 5F3 antibody staining, was actually a MOI of 1. According to the 
Poisson distribution (see 5.3) this is equivalent to 37% uninfected, 37% singly infected 
and 26% multiply infected cells.  
The accuracy gap was only detectable in the case of infected cells and not after 
transfections, which is most likely due to a much higher level of Env expression in 
transfected cells (22-fold, see 3.5.3). Such a high level of Env expression probably 
overburdened the host furin-protease processing, resulting in a higher amount of 
uncleaved Env [233-236] displayed on transfected cells. As it was shown that 
antibodies directed against gp41-epitopes bind more strongly to uncleaved Env 
[237,238], this effect could have contributed to the transfection- / infection-dependent 
binding accuracy of the gp41-specific 5F3 antibody. 
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Nevertheless, it was clearly shown that the 5F3 antibody-based determination of the 
MOI was strongly biased. Therefore, a high number of multiply infected cells had 
probably contributed to the failure of enrichment using MACS Panning (Fig 3.10). 
However, according to the performance of GFP as a marker for transduction, further 
experiments confirmed a stable correlation of GFP and Env, also in terms of 
expression levels (MFI) (see Fig. 3.14). Thus, GFP was validated as a marker for both, 
transduction and Env expression. Therefore, the second proposed vulnerability of 
MACS-panning (see 3.4.3), namely cells with different expression strength of Env were 
not discriminable, has been solved as long as FACS analysis is used. Notably, the 
correlation of GFP versus Env expression (MFI) may only be valid for the V3 model 
library used, and might differ for prospective larger libraries, which probably contain 
more distinct as well as possibly disrupted Envs.  
     
4.1.5 Basic conditions for a QL9-based V3 library panning  
Parameters for an optimal binding of the 447-52D antibody, concerning the 
discrimination between the different V3 variants after a low MOI infection were 
experimentally determined. The resulting characteristic binding pattern (Fig. 3.15) was 
similar to earlier experiments (Fig 3.6 B) using transfected cells. Critical parameters, 
which probably unspecifically bias the panning procedure, were thought to be located 
at the amplification-steps of library processing. Therefore, the growth rates of 
transformed bacteria and the PCR reactions amplifying the complete Env gene were 
probed for differences in the performance between each V3 variant used (3.5.6. / Fig. 
3.16 B). Many factors, such as plasmid sequence, medium, temperature, rpm and 
production vessels (here MTPs) can influence the bacterial doubling-time [239-242]. 
Therefore, it was not unusual to result in 78 ± 4 min, compared to a frequently 
suggested 30 min doubling-time, which is only achievable under ideal conditions [243]. 
However, consistently equal bacterial growth-rates, plasmid DNA yields, plasmid 
genetic stabilities and PCR efficiencies for each V3 variant were documented and 
constituted a promising basis for the development of an unbiased panning procedure.   
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4.1.6 Quantification of enrichment by sequencing and Realtime PCR 
The enrichment of V3 Env variants harvested in each round of panning was evaluated 
by cloning the Env genes of an isolated fraction of cells into an appropriate plasmid. 
Subsequently, transformation of bacteria, propagation of single bacterial clone cultures 
and finally sequence analysis of several bacterial clones (see 2.1) were performed. 
This procedure was intended to work within an acceptable level of accuracy, as each 
clone was precisely assigned to one of the V3 variants according to its sequence. On 
the other hand, this method represents a tedious procedure, as all clones were 
manually maintained. Thus, this procedure was practically limited in the sample size of 
clones that were analyzed, and therefore resulted in an overall statistical accuracy of ± 
10 % (see 3.5.7). A second analysis tool based on Realtime PCR was established, 
allowing to analyze a mixture of plasmid DNA at once (Fig. 3.16 C). The applied 
Realtime PCR approach was specifically designed for the usage in the context of the 
developed model V3 library. It is not intended to be, in that arrangement, a 
manageable method for any proposed larger Env library comprising a great variety of 
sequences. Other techniques such as the comparison of DNA fragment patterns 
during several panning rounds, received after the digestion with a restriction enzyme 
(“fingerprinting”) would be more reasonable in such a case [131].  
Specificity was proven, using manually compounded QL9 V3 library plasmid mixtures. 
Adept primer design allowed performing Realtime PCR reactions, which exclusively 
amplified one desired V3 variant in such a mixture. When the desired variant was 
absent, no or only late (Cycle > 30) unspecific signals were detectable. Since the 
amounts of DNA used in the analyses of panning rounds are about 100-fold less, the 
unspecific signals are supposed to rise at even later cycles (Cycle > 40), and were 
considered negligible. Thus, the theoretical sample size depicted by the calculated 
number of plasmids per ng DNA was dramatically increased, and the statistical 
accuracy was improved up to ± 0.05 % (3.5.7). Moreover, Realtime PCR is less time-
consuming than sequencing. Asides, assembling several Realtime PCR reactions 
turned out to be less tedious than picking and processing several hundred bacterial 
clones.   
Hence, the high consistency of the Realtime PCR results, compared to the clonal 
sequencing analyses, provided a crucial contribution to the validity of the obtained V3 
library panning results (see 3.6).  
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4.1.7 FACS-mediated panning 
As discussed in section 4.1.3, several drawbacks were mentioned, which potentially 
circumvented a successful, specific enrichment of V3 variants using the MACS-
panning. Some of these, such as the determination of MOI and the correlation of Env 
presented on cells, were solved with the implementation of the marker gene GFP. One 
particular issue mentioned earlier (4.1.3), was a general drawback, appearing with the 
usage of MACS, namely the “black-boxed” process of MACS-separations itself (see 
Fig. 3.7/ 8). Particularly, adjusting parameters to compensate avidity effects, triggered 
through varying amounts of displayed Env, was not possible. Thus, the complete 
MACS-mediated selection was switched to a FACS-based selection of cells. The 
improvement made with this decision was mainly constituted in taking the control of 
the selection process on a single cell basis. The combination of a consecutive gating 
strategy, seeking for living, singly and GFP positive cells, and a triangle shaped sorting 
gate, ensured the selection of high 447-52D binding cells (see Fig. 3.18). As GFP was 
shown to correspond with the expression level of Env, the triangle shape of the sorting 
gate was a tool to discriminate between avidity and affinity effects. It was aimed not to 
select for highly expressing cells (avidity effect) with the highest signals in general, but 
to select for a higher ratio of antibody signals in relation to the level of Env expression 
(affinity effect). 
In contrast to the previous experiments made with MACS, Input mixtures of cells as 
well as the mixtures of following rounds, were produced in the same manner. 
Therefore, a two-step process facilitating the linkage of phenotype and genotype was 
applied: (I) The plasmid DNA mixture of V3 variants was transfected jointly with 
packaging and VSV-G plasmids to produce virus particles, (II) Low MOI infections with 
these viruses were made to generate singly infected cells. Utilizing such a procedure 
already for the first round of panning depicts a realistic scenario, as any proposed 
large library (> 1x 103 variants) of Env would not be generated as single plasmid 
clones, but as a mixture of plasmids. Simulating such realistic conditions, the 
challenging probability of undesired multiple infections could be present alongside the 
first infection of cells. However, a valuable evaluation of the FACS-panning system 
was only feasible by using a realistic scenario. 
Preliminary panning experiments were made to demonstrate that in principle the 
discrimination between at least two V3 variants is possible. Therefore, one binding 
(MN) and one non-binding (SF33) variant were chosen as a minimal model library for a 
panning procedure (see 3.6.3). Three different ratios of MN/SF33 infected cells were 
chosen as Input mixtures to evaluate the performance of separation within two rounds 
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of panning. Both, the 5 % and 25 % MN leveled Input mixtures, showed a consistent 
trend of a ∼3-fold enrichment of MN cells throughout two rounds of panning (Fig. 3.19/ 
20). Asides a nearly ∼10-fold enrichment of MN, the first statistical significant 
enrichment was achieved using 50% MN Input mixtures (see Fig. 3.21).  
Taken together, considering the relation of enriched MN to depleted SF33 variants an 
overall enrichment rate of up to ∼10-fold after 2 rounds (#) of panning was achieved 
(see Table 3.4). The calculations are based on the formula !"#$%&! "!#!!!"#$%&! "!#!!!! !!"#$%&!!"!!!#!!"#$%&!!"!!!#! = x-fold enrichment of MN [149].  
 
 
4.1.8 FACS-panning: V3 library screening 
The complete V3 model library, consisting of five V3 variants representing Envs with 
different 447-52D binding capacities (see 3.5.5), was screened by the FACS-panning 
procedure (see 3.6.4). The complete procedure was performed analogously to 
preliminary experiments, in which two V3 variants were used (see 3.6.3). The Input 
mixtures were generated with viruses produced by mixtures of the QL9 based V3 
library (see 2.3.3), resulting in an overall even distribution of ∼1:1 for each V3 variant, 
with only slight differences depending on the analysis tool used.  
After the first round of selection a small trend in favor of MN was measurable, which 
continually rose to a statistically significant enrichment of the V3 variant MN after the 
second round of panning. Notably, the enrichment of the desired variant MN was 
strongly significant (P< 0.01) in relation to any other depleted V3 variant after the 
second round of panning. An overall enrichment rate of 6-fold was achieved as 
calculated by the formula previously discussed (4.1.7), but using the amount of all non-
MN Env variants instead of SF33 only (see Table 3.4). Thus, the enrichment rate is 
within the same range as achieved by preliminary experiments (see 3.6.3/ 4.1.7), 
although more competitive Env variants for the binding to 447-52D were present. 
These encouraging results suggest that with the FACS panning procedure a 
successful screening of larger Env libraries is feasible.  
The only similar lentiviral display system published so far, is represented by that of 
Taube et al. [139]. They used bivalent scFv antibody fragments fused to gp41 and 
presented them on virions as well as on HEK293T cells. By performing a combined 
selection of a first magnetic-bead and second FACS-sorting step, the authors claimed 
to reach a 106-fold enrichment between a binding and non-binding mixture of cells. 
Besides some similarity according to the approach for the selection of cells, Taube et 
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al. strictly produced both examined variants as separate virions, and performed 
infections separately. Thus, this strategy probably suffers from the already discussed 
drawback of having an artificially complete separation, which most likely depicts 
enrichment factors that only apply for artificial conditions. Furthermore, the described 
combination of MACS with the selection of high level expressing cells by a subsequent 
FACS-sorting procedure, most likely promotes avidity instead of affinity effects (see 
4.1.3/ 4). Therefore, their approach was sufficient to discriminate between two strongly 
differing binders, as demonstrated in the study of Taube et al. and similar to the results 
obtained with MACS-panning in this thesis (3.4.2). Actually, the limitations in using 
only separately infected cells, as well as the sorting of mixtures containing more than 
two variants, was resolved by the FACS-panning procedure described in this thesis. 
 
Interestingly, the enrichment of MN in relation to other Env variants (e.g. HXB2 or 
SF33) was not as efficient, as separately detected binding capabilities had suggested 
(Fig. 3.18 C). This may be due to possibly unfavorable, but inevitable circumstances 
caused by the mixed virion production, in order to create the desired realistic scenario 
of panning: (I) Since a two-step process was applied to generate a phenotype and 
genotype linkage (see 3.6), in the first, unlinked step a mixture of pQL9-V3 variants is 
used for the production of virions, which embeds two RNA+ strands (see 1.2). 
Therefore, a chimeric genome of MN joined with e.g. SF33 RNA might be formed. It 
has been shown that predominantly only one copy of the viral genome gets integrated 
[244], while more than two copies lead to apoptosis [245]. Thus a negative effect, 
caused by multiple integration events and a decreased efficiency of the linkage of 
phenotype and genotype seemed limited. Nevertheless, strictly isolating MN variants 
might therefore be delayed; (II) Subsequently to the mixed transfection, virions are 
purified from cell-culture supernatant by ultracentrifugation, leading to aggregation due 
to their high local concentration [246]. Thus, multiple infections of cells are imaginable, 
even though low MOI (0.1) conditions are applied to achieve only singly infected cells 
(see 5.3). Although equal limitations for the integration of more than one copy would 
apply as described for the first step, an influence on the efficiency of the selection 
process remains possible. In order to assess these possibilities in more detail, a 
second QL9 based virus, bearing DsRed [247] instead of GFP would be of worth. A 
mixed production of virus and low MOI infection as described for the panning 
procedure might be performed. Subsequently, FACS analysis might provide 
information to the distribution of multiple integration events by separating infected cells 
according to green, red or yellow (green+red) fluorescence; (III) Aggregates of cells 
were observed after infection and to some extent dissipated using a cell strainer prior 
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to the sorting procedure (see 2.3.8). Therefore, a more stringent single cell gating 
strategy, or the use of cells adapted to suspension growth might be due; (IV) An 
overall sorting efficiency of only 50%, as calculated from the number of sorted events / 
(sort conflicts + sorted events) x 100, provided by the FACS-Aria software (data not 
shown), was observed. Particularly, FACS-sorting may be improved for the selection of 
single cells by further straightening the gating strategy, lowering the concentration of 
applied cells, optimizing the flow-rate of cells or trying to apply alternative cell-types 
that are known to be less sticky (e.g. HEK293F). Though, the specific parameters that 
have caused sorting conflicts remained inaccessible, further efforts in order to increase 
the sorting efficiency could be worthwhile. 
In prospective experiments the FACS-panning might be challenged by using libraries 
of larger diversity for the selection of Env variants featuring the desired bNAb-inducing 
properties. 
 
 
4.2 Conclusion 
A mammalian cell display and panning platform was developed and evaluated in this 
thesis. The ability to enrich an HIV-1 Env variant with the highest affinity to an applied 
antibody in the context of four, less strongly binding Env variants, was successfully 
demonstrated. Thus, when searching for an Env with optimal binding capacities to an 
applied bNAb, the FACS-panning platform provides a tool to screen libraries of 
trimeric, membrane-bound Env variants. 
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4.3 Outlook 
Although a proof-of-concept was shown for the FACS-panning procedure, several 
issues still remain to further improve the procedure. The diversity of any proposed 
library to be screened is restricted to the number of cells that can be screened at once, 
which depends on the instrument and parameters chosen (FACSAria, up to ∼70,000 
events / second). For the FACS-panning procedures in this thesis acquisition rates of 
10,000 events / second were applied. Therefore, efforts should focus on efficiently 
increasing the number of cells that can be used for FACS sorting. Particularly, using 
cells that can be propagated in much higher concentrations, such as HEK293F, as well 
as evaluating the highest possible acquisition rates for FACS sorting, as long as single 
cell populations and purity are not decreased, could be worthwhile.      
The lenti-cellular display and FACS-mediated panning developed in this thesis offer a 
unique solution for bNAb-dependent, affinity-triggered enrichment of Env. Further 
experiments aiming at isolating unknown Env variants that are able to re-elicit bNAbs 
(reverse vaccinology) [122] will involve using larger libraries of Env, as well as several 
bNAbs.  
In addition to simply seeking for an affinity-enhanced Env, neutralization-relevant, 
conformational states of Env will possibly be accessible by addition of cellular binding 
partners of Env, such as CD4 or the co-receptors CCR5 or CXCR4. As mentioned in 
the Introduction (Fig. 1.2) binding of CD4 induces conformational changes in Env, 
enabling the viral entry process, which can be blocked by several bNAbs. It will be part 
of future experiments to learn whether it is possible to screen for a specific Env 
conformation that is preferably bound and then blocked or locked [44] after bNAb 
binding. Therefore, isolating such Env transition state conformations would depict 
interesting candidates for a vaccine that may be able to elicit blocking and therefore 
neutralizing antibodies.  
Besides HIV-1, the developed panning platform is proposed to work with other 
proteins. As demonstrated by e.g. Taube et al. [139], presentation of proteins such as 
scFv antibody fragments was successfully performed using a similar procedure. 
Generally, all proteins capable of being expressed and integrated into a cellular 
membrane are likely to operate within the developed panning platform.   
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5. Appendix 
5.1 Abbreviations 
If not stated otherwise, common abbreviations follow recommendations from the 
Chicago Manual of Style [248], the Gold Book of IUPAC [249] and the White Book of 
the  Joint Commission on Biochemical Nomenclature (JCBN) [250]. References were 
cited following the recommendations of PloS ONE [251]. 
 
Ab antibody 
AIO All-in-One 
ALV Avian Leukosis Virus 
ART anti-retroviral therapy 
Amp ampicillin 
APC Allophycocyanin 
ATCC American Type Culture Collection 
BCR B-cell receptor 
bNAb broadly neutralizing antibody 
bp base pairs 
BSA bovine serum albumin 
CA or p24 capsid protein 
CCR5 chemokine receptor type 5 
CD4 cluster of differentiation 4 
HR heptad repeat 
CIP calf intestine phosphatase 
(h)CMV (human) cytomegalovirus 
CT Cytoplasmic tail 
Ct Cycle threshold 
CTL cytotoxic T lymphocyte 
CXCR4 chemokine receptor type 4 
DC Dendritic cell 
DMEM Dulbecco’s modified Eagle's medium 
DMR aa D474, M475, R476 of HIV-1 Env 
DMSO Dimethyl sulfoxide 
ds double strand 
DTT Dithiothreitol 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme-Linked Immunosorbent Assay 
Env envelope protein 
Fab Fragment antigen binding 
FACS Fluorescence-Activated Cell Sorting 
Fc Fragment, crystallizable = constant 
antibody region 
FCS fetal calf serum 
FP Fusion peptide 
g relative centrifugal force 
Gag group-specific antigen 
gDNA genomic DNA 
GFP Green Fluorescent Protein 
gp41 glycoprotein of 41 kDa = HIV 
transmembrane protein 
gp120 glycoprotein of 120 kDa = HIV surface 
protein 
gp145 glycoprotein of 145 kDa = HIV envelope 
precursor protein with truncated CT 
gp160 glycoprotein of 160 kDa = HIV envelope 
precursor protein 
HA Hemagglutinin, or shortly for HA-tag 
HEK293T human embryonal kidney cell line 293T 
HeLa human cervix carcinoma cell line 
HIV Human Immunodeficiency Virus 
HRP horseradish peroxidase 
ID immunodominant 
IVS Intervening sequence 
IRES Internal Ribosomal Entry Site 
kb kilobases 
LANL Los Alamos National Laboratory 
LB Lysogeny Broth medium 
LTR long terminal repeat 
MACS Magnetic Cell Separation 
MCS multiple cloning site 
MFI mean fluorescence intensity 
MLV Murine leukemia virus 
MOI Multiplicity of infection 
MPER membrane-proximal external region 
mRNA messenger RNA 
MTP Microtiterplate 
NAb neutralizing antibody 
Nef Negative factor 
PBS Phosphate buffered saline 
PE Phycoerythrin 
PEI poly-ethylenimine 
Pol Polymerase, or polymerase precursor 
protein 
poly(A) polyadenylation site 
RT-PCR Realtime PCR 
RLU relative light units 
RLuc Renilla luciferase 
rpm revolutions per minute 
scFv single-chain variable fragment 
SDS Sodium dodecyl sulfate 
SIV (mac) Simian Immunodeficiency Virus (of 
macaque) 
Tat Trans-Activator of Transcription 
TB Terrific Broth medium 
TM transmembrane region 
Tris tris(hydroxymethyl)aminomethane 
TU Transfducing Units 
TZM-bl HeLa-cell derivatives expressing CD4, 
CXCR4, CCR5 and Tat-inducible RLuc 
and β-Gal 
U Unit 
vif viral infectivity factor 
VLP Virus-like particle 
vpr viral protein R 
vpu viral protein U 
VSV-G Viral Stomatitis Virus Glycoprotein 
WPRE Woodchuck Hepatitis Virus 
Posttranscriptional Regulatory Element 
wt wild type 
x fold, in terms of multiplicity 
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5.2 DNA 
5.2.1 Oligonucleotides 
ID Name Sequence 5’3’ 
 All-in-One  
1D1 KpnI-mut fwd CCGTCTATTATGGGCTACCTGTGTG 
1H2 THB_env_FseI-Kozak-NcoI rev CTTATCCATGGTGGCGGCGGCCGGCCCTTATAGCAAAATCCTTTCCAAGC
CCTGTCTTATTCTTC 
1E6 Tat10 fwd (sequencing) GATCCATTCGATTAGTGAACGG 
1D5 RLuc rev (sequencing) CCCTTCCAGTCCCCCCTTTTC 
vpr-mHSA Insertion (via PflMI/ EcoRI ) CCATAGAATGGAGGAAAAAGAGATATAGCACACAAGTAGACCCTGACCTA
GCAGACCAACTAATTCATCTGCACTATTTTGATTGTTTTTCAGAATCTGC
TATAAGAAATACCATATTAGGACGTATAGTTAGTCCTAGGTGTGAATATC
AAGCAGGACATAACAAGGTAGGATCTCTACAGTACTTGGCACTAGCAGCA
TTAATAAAACCAAAACAGATAAAGCCACCTTTGCCTAGTGTTAGGAAACT
GACAGAGGACAGGTGGAACAAGCCCCAGAAGACCAAGGGCCACAGAGGGA
GCCATACACTGAATAGACACTAGAGCTTCTAGAGAGTCGCGCCGCGCGCC
GACGGAGCGGACATGGGCAGAGCGATGGTGGCCAGGCTAGGGCTGGGGTT
GCTGCTTCTGGCACTGCTCCTACCCACGCAGATTTACTGCAACCAAACAT
CTGTTGCACCGTTTCCCGGTAACCAGAATATTTCTGCTTCCCCAAATCCA
AGTAACGCTACCACCAGAGGGGGTGGCAGCTCCCTGCAGTCCACAGCTGG
TCTCCTGGCTCTCTCTCTCTCTCTTCTACATCTCTACTGTTAGAGAATTC 
   
 V3 library  
5F3 THB-5F3-fwd-QL-ZM96 ATAATACGTCTCGCTAGCATGGGAGTGCGGGAGATCCTGCGG 
5G5 THB-5G5-rev-QL-ZM96 ATATTCGTCTCCTCGAGCTAGTAGCCCTGCCGCACTCTGT 
4B7 THB V3-InsertMN fwd TCGGACCTGGGAGAGCTTTTTACACCACCAAAAACATCATCGGCACCATT
AGACAGGCTCATTGTAACATCAGCCGGACCAACTG 
4B8 THB V3-InsertMN rev TGGTGGTGTAAAAAGCTCTCCCAGGTCCGATGTGAATCCGTTTCCGTTTG
TTGTAGTTTGGTCTAGTACACACGATCTCGATGGATCTGTTC 
4B9 THB V3-InsertRF fwd AAGGACCTGGGAGAGTCATCTACGCTACTGGCCAGATCATTGGCGACATC
CGAAAAGCTCACTGTAACATCAGCCGGACCAACTG 
4C1 THB V3-InsertRF rev CAGTAGCGTAGATGACTCTCCCAGGTCCTTTGGTGATGGATTTCCGGGTA
TTGTTGTTGGGTCTAGTACACACGATCTCGATGGATCTGTTC 
4C2 THB V3-InsertCDC42 fwd TGGGACCTGGCCGAGTCTGGTACACAACTGGCGAGATTCTCGGAAACATT
CGGCAGGCTCACTGCAACATCAGCCGGACCAACTG 
4C3 THB V3-InsertCDC42 rev CAGTTGTGTACCAGACTCGGCCAGGTCCCAGAGTGACTCGTTTTCGGGTG
TGGTTGTTGGGTCTAGTACACACGATCTCGATGGATCTGTTC 
4C6 THB V3-InsertHXB2 fwd TTCAGAGAGGACCTGGACGAGCTTTTGTGACAATCGGGAAAATCGGCAAC
ATGAGACAGGCTCACTGTAACATCAGCCGGACCAACTG 
4C7 THB V3-InsertHXB2 rev TCACAAAAGCTCGTCCAGGTCCTCTCTGAATTCTAATCCGTTTCCGGGTA
TTGTTGTTGGGTCTAGTACACACGATCTCGATGGATCTGTTC 
4C8 THB V3-InsertSF33 fwd CTGGACCTGGCAAAGTGCTCTACACTACCGGGGAAATCATTGGAGACATT
CGGAAGGCCTACTGTAACATCAGCCGGACCAACTG 
4C9 THB V3-InsertSF33 rev CGGTAGTGTAGAGCACTTTGCCAGGTCCAGATGTGATCCGTCGCCGTCTA
TTGTTGTTGGGTCTAGTACACACGATCTCGATGGATCTGTTC 
4D9 ZM-96-seq-For (sequencing) GACAGACGACAGCGAGACAGG 
4E1 ZM96-seq-Rev (sequencing) CTCTCAGCAGGTTGCTCTGC 
4F1 THB ZM96 seq-1-fwd (sequencing) ATCCCCATCCACTACTGCG 
   
 QL-plasmid construction  
4A1 T7-prom fwd TAATACGACTCACTATA 
1A4 pC-BGH-Rev GCAACTAGAAGGCACAGTCGAGG 
5G6 THB-5G6-fwd-QL-BsmB1-ccdB ATAATAACGCGTGCTAGCGAGACGCCGGAATTGCCAGCTGGGG 
5G7 THB-5G7-rev-QL-BsmB1-ccdB TATATACATATGCTCGAGGAGACGTTATTAAATGCCCCAAAACATCAGG 
6E1 THB-MluI-SV40-fwd ATTATACGCGTCTGTGGAATGTGTGTCAGTTAGG 
6E2 THB-KpnI-SV40-rev ATTATGGTACCCGAAAATGGATATACAAGCTCC 
6F4 THB-6F4-SV40-fwd CTGTGGAATGTGTGTCAGTTAGG 
6F5 THB-6F5-GFP-rev TTACTTGTACAGCTCGTCCATGC 
4E9 THB-GFP rev sNRP1 TATTGAATTCCATTTCGTATTTTATTTCTATTACTTGTACAGCTCGTCC 
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4G7 GFP-FOR-EcoRI CTCTCTGAATTCATGGTGAGCAAGGGCG 
4G8 GFP-Rev-XbaI TCCTGAAGATCTTTACTTGTACAGCTCGTCC 
6H1 THB-6H1-Nde1-IRES-fwd TATTCATATGCGAGCATGCATCTAGGG 
6H2 THB-6H2-Nde1-GFP-reverse TATTCATATGTTACTTGTACAGCTCGTCCATG 
6H3 THB-6H3-YFP-SV40pA-rev GCAGTGAAAAAAATGCTTTATTTG 
3D2 Seq-pLIB-For-1 (sequencing) TCTTCCATTTCAGGTGTCGTG 
5H7 THB-5H7-rev (sequencing) TTCCACCAGATCGAGAAGGAGTTCAGCGAGGTGGAGGGCCGCATCCAGGA
CCTGGAGAAGTACGTGGAGGACACCGGCAGCACCCAGGAATGGGAGCGGA
AGGTCGACTTC 
6H8 THB-6H8-QL5-seg-f (sequencing) TCTGTTGAATGTCGTGAAGGAAG 
6H9 THB-6H9-QL5-seq-r (sequencing) TGCAAAGGGTCGCTACAGAC 
6I1 THB-6I1-QL5-seg-f (sequencing) GGCTACGTCCAGGAGCGC 
6I7 THB-6I7 ccDB-PmeI-f TAATAGTTTAAACGCTAGCGAGACGCCGGAATTGCCAGCTGGGG 
6I8 THB-6I8 ccDB-BamHI-r ATATAGGATCCCTCGAGGAGACGTTATTAAATGCCCCAAAACATCAGG 
6I9 THB-6I9-f-NdeI-syn.Intron TATTCATATGCTAAGTAAGGATCCACTAGTAACGG 
7A1 THB-7A1-pIRES2-eGFP-f TATTCATATGTCTGCAGTCGACGGTACCGC 
8B2 THB-8B2-f-MluI-GFP TATTACGCGTGCCATGGTGAGCAAGGGCGAGGAGCTGT 
8B3 THB-8B3-r-NheI-IRES TATTGCTAGCCGGTCCGCTTTGCGGACTGATGGGGAA 
8B4 THB-8B4-r-NheI-TaV TATTGCTAGCTGGGCCAGGATTCTCCTCGACGTCACCGCATGTTAGCAGA
CTTCCTCTGCCCTCCTTGTACAGCTCGTCCATGCCGAG 
8B5 THB-8B5-f-MluI-eGFP TATTACGCGTGCCACCATGGCCACAACCATGGTGAGCAAGG 
8B6 THB-8B6-f-MluI-synGag TATTACGCGTGCCGCCAGCATGGGCGCCAGGGCCA 
8B7 THB-8B7-r-SpeI-synGag TATTACTAGTTCACTGGCTGCTGGGGTCGTTGCCG 
8D5 THB-8D5-QL9-seq  AGGACATCATCAGCCTGTGGG 
8D6 THB-8D6-QL9-seq  CTGGAAATCACCACCCACAG 
8D7 THB-8D7-QL9-seq  AGCATCACCCTGACCGCCC 
8D8 THB-8D8-QL9-seq  ACAGAACGAGAAGGACCTGC 
8D9 THB-8D9-seq-f  CATGGTCCTGCTGGAGTTCGTG 
9B3 THB-seq-f-9B3 TTACCGGATACCTGTCC 
9B4 THB-seq-f-9B4 AGGATCTTCACCTAGATCC 
9B5 THB-seq-f-9B5 ACTCATGGTTATGGCAG 
9B6 THB-seq-f-9B6 TATGGTGCACTCTCAGTAC 
9B7 THB-seq-f-9B7 TAAACCTGTGATTCCTCTG 
9B8 THB-seq-f-9B8 AGATCCTGCATATAAGC 
9B9 THB-seq-f-9B9 AACATCAGAAGGCTGTAG 
9B10 THB-seq-f-9B10 ATCAAGCAGCTCCAGGC 
9B11 THB-seq-f-9B11 ATCTCGACGGTATCGATG 
9B12 THB-seq-f-9B12 TTCGATAAGTCTCTAGCC 
9C4 THB-seq-f-9C4 CATATGATAATCAACCTCTGG 
9C5 THB-seq-f-9C5 TTAAACCCGCTGATCAGC 
9C6 THB-seq-f-9C6 AACAGGGACTTGAAAGCG 
9C7 THB-seq-f-9C7 AACAGAGAGGAATCTTTGCAGC 
 
 
 
 
 
 QL-cloning  
8H1 THB-8H1-for TGAGTTGGATAGTTGTGG 
8H2 THB-8H2-rev GGATTTATACAAGGAGGAGA 
5I3 THB-5I3-fwd-QL-ZM96 ATAATACGTCTCGCTAGCATGGGAGTGCGGGAGATCCTGCGGAACTGGCA
GCGGTGGTGG 
5I4 THB-5I4-rev-QL-ZM96 ATATTCGTCTCCTCGAGCTAGTAGCCCTGCCGCACTCTGTTCACGATGGA
CAGCACGGCG 
   
 Realtime PCR  
8H9 THB-8H9-MN-rev-2 GATGATGTTTTTGGTGGTG 
8I1 THB-8I1-RF-rev-2 AGTGAGCTTTTCGGATGT 
8G1 THB-8G1-CDC4-rev TCTCGCCAGTTGTGTACC 
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8G3 THB-8G3-HXB2-rev GGTCCTCTCTGAATTCTA 
8G4 THB-8G4-SF33-rev CCCGGTAGTGTAGAGC 
8G5 THB-8G5-V3-for GGAAGGCATCATCATCAG 
8I2 THB-8I2-V3-rev CGATCTCGATGGATCTGTTC 
8I3 THB-8I3-V3-Sonde (FAM-BHQ1) TTTCACGTTGTTGGTCAGGTT 
 
5.2.2 Plasmids 
Name  
pNL4-3 pUC [252] based vector, including the complete HIV-1 genome of the strain NY5/BRU 
(LAV-1), Accession number: AF324493.1 [253] 
pTN7-Stop Lentiviral vector based on NL4-3, autologous Env ORF interrupted, includes R.Luciferase 
inserted into the Nef ORF [181-184] 
pTN-AIO Derivative of pTN7-Stop, see 3.2.2 
pTN-AIOHSA Derivative of pTN-AIO, see 3.2.2 
pTN pack Lentiviral packaging construct [184] 
pWPXLd Lentiviral vector, Addgene plasmid #12258, Addgene Inc., Cambridge, USA 
pVSVG Envelope of vesicular stomatitis virus cloned into pcDNA3.1(+). [171] 
pPCR-Script Amp Commercially available vector, Agilent technologies # 211188 
pcDNA3.1(+) Commercially available vector, Invitrogen # V790-20 
pcDNA3.1(+) QL Derivative of pcDNA3.1(+), including a CcdB cloning cassette inserted at the MCS 
pEGFP-C1 Commercially available eGFP expressing vector, Clonetech, GenBank # U55763 
pEYFP-C1 Commercially available eYFP expressing vector, Clonetech, Catalog # 6005-1 
pMACS LNGFR-IRES Commercially available IRES vector, Miltenyi Biotec, Catalog # 130-091-887 
pIRES2-EGFP Commercially available IRES2-eGFP vector, Clonetech, Catalog # 6029-1 
pQL1 – pQL11  Lentiviral vectors including a CcdB cloning cassette, see 3.5.1 
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5.2.3 V3 library sequences 
V3 loop of the respective constructs 
 
pQL9-MN 
 
 
pQL9-RF 
 
 
pQL9-CDC42 
 
 
pQL9-HXB2 
 
 
pQL9-SF33 
 
 
- The respective V3 loops are underlined in yellow. 
- The same variants were also cloned into pcDNA3.1(+) QL 
 
V3 library sequence alignment 
 
- The sequence range of the V3 loop is depicted. 
- The respective V3 loops are underlined in yellow. 
- The sequence of MN is set as reference. Deviating nucleotides of the other variants are highlighted.  
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5.3 MOI and infectivity 
Poisson distribution 
 
- e = Euler's constant 
- Poisson distribution is used to determine the MOI. 
- The probability P (n > 0) approximately equals MOI (m) for small values of m (m < 0.5)   
Pn =
mn × e−m
n!
Poisson distribution: 
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